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Abstract 
Bacteria can be found as surface adhered, structured colonies that generate an extracellular 
matrix, known as a biofilm. Biofilms are recalcitrant to antibiotics. Therefore, treatments of 
biofilm infections are limited, especially in terms of indwelling medical devices. The major 
causes of biofilm-associated infections on medical implants are S aureus and 
S. epidermidis. This work sought to identify and characterise compounds with 
antistaphylococcal antibiofilm activity.  
Initial studies were performed as a part of the COATIM consortium. The antibacterial and 
antibiofilm activity of 56 compounds provided by members of the consortium were assessed 
against bacterial and fungal organisms. The top five (4-45, CIM008405, P1a-PEP1, P2-5  Tocris 
2611) compounds were selected for further characterisation based on their  antibiofilm activity 
and toxicity. The MOA of the five compounds were characterised in S. aureus. All five 
compounds caused membrane perturbation, but Tocris 2611 was the only one to exhibit some 
prokaryote selectivity. In addition, Tocris 2611 eradicated preformed staphylococcal biofilms 
by  sterilising the biofilm cells and had low resistance potential. The five compounds were then 
coated on titanium substrates (representing dental/orthopaedic implants) and tested for their 
ability to prevent biofilm formation in vitro and in vivo against biofilm colonisation in vivo and 
in vitro. No useful antibiofilm activity was observed. 
Finally, three chemical libraries of biologically active small molecules were screened for 
adjuvants of antibiotics ciprofloxacin and rifamipcin against S. aureus biofilms, and rifampicin, 
fusidic acid or linezolid against planktonic E. coli.  No potentiators were determined against S. 
aureus biofilms at the tested concentrations. However, several synergistic interactions were 
initially identified against E. coli, but had limited antibacterial activity against multi-drug 
resistant (MDR) pathogens.  
Due to the limitations of current antibiofilm strategies and the ability of bacteria to adapt 
continuously, it is important to consider combining multiple approaches to target biofilms 
successfully. 
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Chapter 1 
Introduction 
1.1 Introduction to bacterial biofilms 
The evolution of antimicrobial resistance is a natural phenomenon that is exacerbated by the 
exposure of bacteria to antimicrobial drugs. Due to the natural phenomenon of antimicrobial 
resistance and the misuse of available antimicrobial treatments, antibiotic resistance is now a 
worldwide problem. An estimated 50% of all prescribed antibiotics are not needed or fully 
effective as prescribed and unless action is taken to improve infection prevention and antibiotic 
use, the world is set to enter a post-antibiotic era (CDC, 2013). Presently, a serious threat to 
human welfare is multi-drug resistant (MDR) bacteria, such as Gram-positive organism 
meticillin-resistant Staphylococcus aureus. Individuals infected with MRSA are estimated to be 
64% more likely to die from infection than those with a non-resistant strain (WHO, 2014). An 
additional problem in treating antibacterial infections and MDR bacteria is the formation of 
bacterial biofilms. 
Biofilms are bacteria within multicellular, structured communities adhered to an inert or 
biological surface and encased in a self-produced extracellular matrix (Lopez et al, 2010). It is 
the most common form of bacterial culture found in the natural environment, with an estimated 
99% of microorganisms living in these communities (Carvalho et al, 2007). Biofilms can 
develop in a range of different environmental conditions, including water supply systems, 
hydrothermal vents and living tissue (Carvalho et al, 2007). 
Bacteria within the biofilm are phenotypically distinct from those in the planktonic state (Lopez, 
2010).  Notably, biofilm-associated bacteria exhibit reduced susceptibility to antibacterial 
treatment (particularly due to the presence of slow-or non-growing (SONG) bacteria, including 
persister cells) (O’Neill, 2011). Biofilms high recalcitrance to antibiotic treatment is especially 
problematic in the clinical environment, where biofilm formation is estimated to be involved in 
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80% of all bacterial infections in humans, such as osteomyelitis, endocarditis and infections of 
implanted medical devices (Römling and Balsalobre, 2012).  
Numerous bacterial species form biofilms, but some of the most frequent causes of biofilm-
associated infections include Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus 
epidermidis, Klebsiella pneumoniae and Enterococcus faecilis. The most significant of these in 
terms of biofilm-associated infections and healthcare costs are S. aureus and S. epidermidis 
(Costerton et al., 1999). Indeed, they are considered to be the cause of up to 70% of biofilm 
infections on catheters (Treter and Macedo, 2011), and up to 50% of biofilm infections on 
prosthetic heart valves (Nagpal et al, 2012). Since these types of infection can be untreatable, 
they are especially problematic in the clinical setting, often resulting in the failure and 
subsequent surgical removal of the implanted medical device (Johnjulio et al, 2012 and 
Carvalho et al, 2007). This type of revision surgery is stressful for patients, increases the 
duration of hospital stays and adds to hospitalization costs (Carvalho et al, 2012). Biofilm-
related corrective surgery costs in Europe are estimated at €800 million per year, and the 
reduced susceptibility of biofilms to antibacterial killing is driving and directing research into 
the development of new antibacterial agents, in order to tackle this growing problem (O’Neill, 
2011). 
However, it is also important to acknowledge that not all biofilms are detrimental to health and 
that some biofilms are beneficial and necessary for our survival. For example, biofilms formed 
by the host microbiota can act as a defence mechanism by protecting against foreign pathogens 
(Belkaid et al, 2014). An example of this is the gut microflora which protects against food borne 
pathogens which could potentially colonise the gut and cause infection (Lee et al., 2000).  
1.1.1 Biofilm formation 
Although biofilm formation has been found to differ between bacterial species, and is impacted 
by both genetic and environmental factors, there are two steps that are considered to be 
universal in all biofilm-forming bacteria; attachment, followed by maturation. However, these 
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can be further broken down into five general stages of development; reversible attachment, 
irreversible attachment, growth, maturation and finally dispersal (Figure 1.1). 
 
Figure 1.1 Five steps of biofilm formation, from planktonic culture to structured biofilm 
community. Reversible attachment (1): planktonic bacteria adhere to an inert or living surface; 
Irreversible attachment (2): affixed bacteria begin to form a biofilm, resulting in irreversible 
attachment; Growth (3): the biofilm structure begins to grow and mature. Bacteria will now be 
protected from environmental stresses by the extracellular matrix; Maturation (4): continued 
development and further maturation of the biofilm; Dispersal (5): planktonic bacteria are 
dispersed from the biofilm, which can result in the spread of the infection.  Image adapted from 
Monroe (2007). 
1.2 1 
For a biofilm to form, planktonic bacterial cells must first attach to a biological or inert surface 
(Figure 1.1). Often for attachment to occur, trace organic or inorganic molecules (bridging 
molecules) must be absorbed onto the surface (Lindsay et al, 2006). This is known as surface 
conditioning, and is thought to neutralize any charge or free energy that may have inhibitory 
effects. Surface coated bridging molecules, together with forces such as Van de Waals, electro 
static and hydrophobic, have been suggested to cause an initial attraction between the bacterial 
cells and the surface (Lindsay et al, 2006). Attachment also requires bacteria to be within close 
range of the surface. Existing structural features of the bacterial cells, such as flagella, can be 
used to reach the surface (Carvalho et al, 2007). Otherwise bacteria can rely on mechanical 
processes like shear force. Primary attachment is weak, and as a consequence reversible (Garrett 
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et al, 2008). Bacteria can therefore dissociate from the surface and revert to non-adhered, 
planktonic cells.  
Bacterial cells become irreversibly bound to the surface by either of two pathways; production 
of EPS or surface receptor protein (Monds et al, 2009). Subsequently, attached bacteria begin to 
divide, and accumulate with one another, sometimes travelling across the surface to join 
existing accumulations of cells (Aparna et al, 2008 and Monds et al, 2009). As biofilms enter 
the growth phase, newly formed colonies of bacteria continue to divide, and there is a release of 
signalling molecules, a process known as quorum sensing (del Pozo et al, 2007).  Quorum 
sensing is a population density dependent programming system used by bacteria to coordinate 
activity and gene expression amongst the community (Miller et al, 2001). The levels of these 
signalling molecules increase in a cell density dependent manner until a threshold is passed, and 
are detected by receptors on the bacterial surface (Albuquerque et al, 2014). When the chemical 
molecules bind to the specific receptors it causes the transcription of particular genes in the 
majority of the cells at roughly the same time (Ng et al, 2015). Bacteria are therefore releasing, 
detecting and reacting to the chemical signals in response to the dynamic environment and thus 
regulating specific genes which control important biological functions (Miller et al, 2001). 
Quorum sensing therefore allows bacteria to assess their surrounding conditions and adjust gene 
expression accordingly to increase bacterial survival (Withers et al., 2001 and Ng et al, 2015). 
As the biofilm matures, a multicellular structure is formed, including further assembly of the 
exopolysaccharide matrix. At this stage, other species of bacteria or fungi can also become 
associated with the surface, forming a polymicrobial biofilm. For example, in clinical settings, 
S. aureus is thought to be the third most prevalent bacterium found in polymicrobial biofilms 
with Candida albicans (Peters et al., 2012). 
The final stage of formation is dispersal (Kaplan et al, 2010). This is where the mature biofilm 
can release bacterial cells, which return to the surrounding planktonic community. Dispersal 
contributes to the spread of infections and colonization of new surfaces (Kaplan et al, 2010).  
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1.1.2 Biofilm composition/structure 
As with biofilm formation, biofilm structure varies between different bacterial species and is 
affected by environmental factors, such as the source of nutrients (Hall-Stoodley et al, 2004). It 
is currently accepted that there is a general stratified structure consisting of three defined 
sections common to all biofilms (Donlan, 2002). The bottom layer of the structure attaches the 
biofilm to the surface. The next ‘layer’ is composed of colonies of either multiple or single 
species of bacteria, and finally a surface film (or extracellular matrix) encompasses and embeds 
the bacteria (Aparna et al, 2008). The extracellular matrix is a hydrated polyanionic complex, 
which encompasses and contains DNA, proteins and extracellular polymeric substance (EPS) or 
exopolysaccharides, which are secreted by the bacteria. This EPS component can comprise 
between 50% and 90 % of the biofilm’s organic carbon (del Pozo et al, 2012). Each component 
of the EPS plays an important role in the biofilm. For example, the extracellular DNA (eDNA) 
functions as an intercellular connector, whilst enzymes break down EPS biopolymers to 
molecules, such as carbon, which can be used as an energy source for the bacteria within the 
biofilm. Another common structural feature found within biofilms are mushroom shaped 
microcolonies (Aparna et al, 2008). However, this is not the only type of architecture the 
biofilm can assume, as the biofilm structure can also be flat, depending on the nutrient source of 
the bacteria (Hall-Stoodley et al, 2004). Additionally, to ensure that there is not an accumulation 
of waste material, which could potentially be toxic to the bacterial cells, there are also water 
channels which occur between the microcolonies in the biofilm which, it has been suggested, 
allow the community to clear any toxic metabolites and also provide a route for mineral and 
nutrient uptake (Aparna et al, 2008). 
 
1.2 Staphylococcal biofilms  
One of the primary bacterial genera of interest with regards to biofilm infections are the Gram-
positive staphylococci (Darouiche et al, 2004 and Zimmerli et al., 2004). There are at least 40 
species of staphylococci, most of which are ordinarily harmless, inhabiting mammalian mucous 
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membranes and the skin (Kiedrowski et al, 2011). S. aureus is estimated to be in the anterior 
nares of 20% of the population (Rongpharpi et al, 2013), whilst S. epidermidis, which is 
coagulase negative, is present on most of the population (Becker et al, 2014). Furthermore, S. 
aureus and S. epidermidis are the most common cause of hospital-acquired infections, in 
addition to being the leading cause of biofilm-associated infections, particularly on indwelling 
medical devices (Kiedrowski et al, 2011).  
The ability of staphylococci to form a biofilm provides a survival advantage in the ordinarily 
adverse environments of the human host, in addition to the production of virulence factors, such 
as toxins, catalase and coagulase (Tenover et al, 2000). Indeed, most staphylococci infections 
are biofilm-associated (Otto et al, 2008).  
1.2.1 Biofilm formation in staphylococci 
Staphylococci bind to surfaces using microbial surface components recognizing adhesive matrix 
molecules (MSCRAMMs) (Patti et al, 1994). There are approximately 20 different MSCRAMM 
proteins (Walsh et al, 2008). These surface proteins associate with serum proteins and host 
extracellular matrix molecules mediating attachment, such as fibronectin binding protein A and 
B (FnBPA and FnBPB) which chiefly bind to the large glycoprotein fibronectin (Sepziale et al, 
2014). These adhesins are attached to the staphylococcal cell wall, and are able to bind host 
proteins, including fibronectin, collagen and elastin (Speziale et al, 2014). The general overall 
structure of MSCRAMMs can be broken into three domains (Foster et al, 2014). Firstly, the 
domain is either covalently or non-covalently bound to the surface of the bacteria, followed by 
the cell-wall spanning domain and the final domain that is exposed for binding (Foster et al, 
2014).  In addition to the role of MSCRAMMs in staphylococcal surface adhesion, the type of 
surface can also influence the attachment process (Otto et al, 2010). It has been reported that 
staphylococci show preferential attachment to plastic surfaces, which may be a factor in the 
significance of staphylococcal biofilm infection on implanted medical devices (Sousa et al, 
2008).  
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Following attachment, staphylococci begin to produce substances such as extracellular DNA, 
proteins, teichoic acid and polysaccharide intercellular adhesin (PIA) that form the extracellular 
matrix (Garrett et al, 2008). Furthermore, PIA, which consists chiefly of poly-N-
acetylglucosamine (PNAG), is the primary compound that causes intercellular adhesion, a major 
part of staphylococcal biofilm maturation (Rohde et al., 2010). PIA is a partially de-acetylated β 
1-6-linked N-acetyleglucoasmine homopolymer, which is generated through the intercellular 
adhesion (ica) operon (consisting of biosynthetic gene icaADBC, aswell as transcriptional 
repressor IcaR) and accessory membrane proteins (Arciola et al 2015). However, the generation 
of PIA is not a requisite for biofilm development in staphylococci, as PIA-independent biofilm 
formation can also occur (Valle et al, 2003). It has been suggested that adhesive proteins will 
replace PIA during PIA-independent biofilm formation (Otto et al, 2015). 
The major transcriptional regulators of genes involved in biofilm formation apart from IcaR 
include alternative sigma factor (SigB), which functions to increase the generation of proteins at 
the cell surface which promotes the formation of the biofilm, the accessory gene regulator (agr), 
which functions in the dispersal of the biofilm, staphylococcal regulator (sarA), which like SigB 
is involved in biofilm formation, ArlR-ArlA two component system (TCS), which again is 
involved in biofilm formation, and finally the teicoplanin-associated locus regulator (TcaR) 
which is involved in the regulating the expression of the ica operon (Cerca et al, 2008). 
After surface attachment, and intercellular aggregation, the maturation phase of staphylococcal 
biofilm development includes the 3-dimensional structuring of the biofilm. As mentioned 
previously (section 1.1.2), this includes mushroom-shaped towers and water channels, providing 
oxygenation removal of waste (Tilahun et al, 2016). Finally, bacterial cells may be released 
from the mature biofilm, known as dispersal. These dispersed cells may travel to and attach to 
new surfaces, resulting in biofilm formation of that surface (Kaplan et al, 2010).  
1.3 Biofilm recalcitrance to antimicrobials 
Biofilm infections are rarely able to be resolved by the host immune system, or with antibiotics. 
Biofilm formation is therefore central to the pathogenesis of many bacteria and resistance can be 
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through more than one mechanism (del Pozo and Patel, 2007). The reasons that biofilms display 
such a high level of recalcitrance to antimicrobials are thought to be through inherent 
mechanisms of resistance or the transfer of genetic material (Norrby, 1991, O'Neill, 2011).  
 
1.3.1 Inherent mechanisms of antibiotic resistance in biofilms  
1.3.1.1 Stress Response/restricted penetration 
It has been suggested that, as the bacteria within biofilms are enclosed in an exopolysaccharide 
matrix, the diffusion and penetration of antimicrobial drugs could be restricted. For example, 
the positively-charged aminoglycosides are prevented from penetrating the negatively charged 
extracellular matrix, due to binding to the negatively charged matrix polymers (Aparna and 
Yadav, 2008, del Pozo and Patel, 2007, Lewis, 2001, Shigeta et al., 1997). Mature biofilms are 
also thought to contain altered micro-environments, for example due to the build-up of waste 
products, low oxygen concentrations, and pH, which may further inhibit the activity of the 
antimicrobial agent (del Pozo and Patel, 2007). However, restricted penetration has been shown 
not to apply for most classes of antibiotics. For example, fluoroquinolones easily travel across 
the extracellular matrix of the biofilm (del Pozo and Patel, 2007, Lewis, 2001). Alternatively the 
antimicrobial agent may penetrate the biofilm, but quickly become bound and inactivated by 
enzymes produced by the bacteria against the active drug (del Pozo and Patel, 2007).  Also, 
when bacteria are exposed to conditions which do not favour growth they are able to up-regulate 
genes, known as stress-response genes, resulting in rapid adaptation (del Pozo and Patel, 2007). 
These genes cause a change in the bacterial phenotype which is more resistant to the 
surrounding environmental stress (Waters and Storz, 2009). For example, the ndvB gene in 
Pseudomonas aeruginosa, has been found to be required for the production of periplasmic 
glucans. which prevent tobramycin from reaching its target through direct interaction (del Pozo 
and Patel, 2007). 
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1.3.1.2 Evasion of host immune defence 
Not only can biofilms display decreased susceptibility to antimicrobial killing, they can also 
display a decreased susceptibility to the host immune system. This can be through decreased 
expression of significant antigens, increased resistance to phagocytosis or resistance to killing 
by polymorphonuclear leukocytes (Bradley et al., 2003). This resistance is thought to be 
conferred by the EPS, which forms a physical barrier against the attacking components of the 
host immune system, decreasing the efficiency of host immune killing compared to killing of 
single bacterial cells and secreting molecules which chemically inactivate attacking immune 
cells (Foster, 2005). For example, polysaccharide intercellular adhesins (PIA) found in S. 
epidermidis, are charged homopolymers which hold cells together in the biofilm but also 
contribute to evading the host immune defence by promoting resistance to antimicrobial 
defensin peptides (Foster, 2005). S. epidermidis mutants lacking PIA have been shown to be 
increasingly predisposed to killing by neutrophils and host peptides such as LL-27, β-defensin 3 
and dermicidin (Foster, 2005). 
 
1.3.1.3 Antibiotic survival in biofilms 
Antibiotic survival can be defined as tolerance to killing by bactericidal antibiotics, whilst still 
being sensitive to an antibiotics inhibitory mechanism, i.e. the bacteria can survive in the 
presence of antibiotics, but not grow (O'Neill, 2011). By contrast ‘resistance’ is described by the 
World Health Organisation as “...recalcitrance of a microorganism to an antimicrobial 
medicine to which it was previously sensitive.” (WHO, 2012), which is caused by heritable 
genetic mutations. Antibiotic survival in biofilms is generally through two main mechanisms; 
drug indifference and persistence (Figure 4) (Hall-Stoodley et al., 2004). Drug indifference is 
considered to be a phenotypic state of quiescent (non-dividing) bacteria, which the majority of 
antibacterial agents are unable to kill (Levin and Rozen, 2006, McDermott, 1958, O'Neill, 
2011). The more established an infection is, the more non-growing, stationary phase cells are 
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present and the less effective the antibiotic agent will be (Levin and Rozen, 2006). Therefore, if 
cells are not undergoing active metabolism, the non-growing cells become ‘indifferent’ to the 
antibacterial agents because of a lack of ‘target corruption’. Target corruption is where the 
antibiotic kills the cell, not by directly inhibiting the target to which it binds, but through 
altering its function resulting in the production of toxic derivatives. It is these downstream by-
products which lead to cell death (Lewis, 2007). For example, aminoglycosides cause cell death 
by causing the cell to make misfolded toxic proteins, via disruption of translation (Lewis, 2007). 
Persistence (adaptive resistance, phenotypic tolerance) is described as a subpopulation of a 
multiplying bacterial population which bactericidal antibiotics are unable to eliminate 
(Kiedrowski and Horswill, 2011, Gotz, 2002). Ineffective elimination is due to the persistent 
cells undergoing a much slower growth rate compared to the remainder of the population 
(Lewis, 2007). The reduced growth rate is suggested to be through numerous metabolic genes 
being down-regulated. This allows these quiescent cells to endure high levels of antibiotics, 
without displaying classic resistance mechanisms. Persistent cells also have the ability to reform 
biofilms following antibiotic cessation (Miller and Bassler, 2001). Persisters are therefore 
another important factor to consider in biofilm resistance (Figure 1.2). 
However, it is still uncertain whether persister cells are undergoing a completely separate state 
to those undergoing drug indifference, or if they are just a subpopulation of more antibiotic 
tolerant cells.  
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Figure 1.2 Model of antibiotic survival due to drug indifference/persistence. Panel (a): Biofilm 
with no challenge from antibiotic agent, and unsuccessful immune attack; Panel (b): Antibiotic 
chemotherapy kills the non-tolerant (grey) bacterial cells within the biofilm, whilst the host 
immune system targets and kills both the tolerant (red) and non-tolerant (grey) planktonic cells; 
Panel (c): Following antibiotic cessation remaining bacterial cells due to drug 
indifference/persistence repopulate the biofilm, causing the infection to recur. Adapted from 
Lowy (1998) 
(Lowy, 1998) 1.2 2 
1.3.2  Gene transfer  
Pathogenic bacteria have developed numerous strategies to resist the action of antibiotics, 
including modification and inactivation of the drug, exclusion of the antibiotic and alteration of 
the target (Kumar et al., 2012). The origin of antibiotic resistance genes in pathogenic bacteria is 
unclear, but it is thought that horizontal gene transfer (HGT) of this genetic material is largely 
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responsible for the increasing incidence of antibiotic resistant infection worldwide (Davies J., 
2010). HGT, which includes transduction, transformation and conjugation (Rees et al., 2009), 
has been found to occur at a higher frequency in biofilms than bacteria in the planktonic state 
(Madsen et al, 2012). Thus, plasmids that code for antimicrobial resistance (or virulence factors) 
can be transferred between cells, enabling previously non-resistant bacteria cells to start 
exhibiting resistance or increased virulence (Schroeder et al., 2017).  For example, in biofilms 
formed by Klebsiella pnemoniae, genes encoding β-lactamase can be transferred between cells, 
which allow them to quickly inactivate β-lactams, such as ampicillin (del Pozo and Patel, 2007). 
Resistance has a clinical impact on patients, leading to more treatment failures, higher mortality, 
prolonged length of hospital stays and higher costs (Warnes SL., 2012). Emphasizing the 
importance of efforts to limit their emergence and spread. 
 
1.4 Antibiofilm surfaces  
Biofilms can form on indwelling medical devices (e.g. cardiac pacemakers, joint prosthesis) due 
to the surfaces of these necessary implants providing an ideal scaffold for bacterial attachment 
and biofilm formation. The consequent highly resistant infection ultimately results in the 
requirement for surgical removal of the implanted device. However, this is costly, stressful for 
the patient and not always immediately possible, such as in the case of joint prosthesis or in 
critically unstable patients for whom surgery may put their lives at risk (Kiedrowski and 
Horswill, 2011).  Thus, the need for alternative treatments is crucial. One such alternative is the 
development of anti-biofilm coatings to cover indwelling medical devices. Currently, medical 
implants which have been developed have a porous surface, enabling rapid osseointegration. 
However, it has recently been discovered that such surfaces pose an enhanced risk of infection 
from biofilms (Darouiche, 2004).  
All current antibiofilm coatings function by impeding bacterial attachment and consequent 
biofilm maturation, through the incorporation of conventional antibiotics, or through the 
delivery of silver (or occasionally zinc) ions.  Although these methods display some positive 
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results, such as reduced biofilm formation, they also result in side effects that include toxicity, 
hypersensitivity and the development of bacterial resistance to antibiotics (Dror et al., 2009). 
When evaluating antibiofilm coatings for medical implants, it is important to consider that even 
with the same type of antibiofilm surface, different types of implants may display different level 
of effectiveness in the disruption/prevention of biofilm formation (Dror et al., 2009). For 
example, urinary catheters impregnated with silver were found to increase the numbers of 
staphylococcal bacteriuria infections, whilst endotracheal tubes impregnated with silver reduced 
the incidence of ventilator associated pneumonia (VAP). There is therefore a need for the 
development, improvement and standardisation of antibiofilm coatings, focusing on either 
complete eradication of the biofilm, or prevention of biofilm formation (Dror et al., 2009). One 
novel approach to biofilm eradication is to disrupt the biofilm maturation process through 
interference with autoinducer signalling pathways (Brözel et al., 1995, Davies et al., 1993, 
Sauer and Camper, 2001). For example, the organic chemical compounds furocoumarins are 
able to inhibit cellular autoinducer signalling, which results in the inhibition of biofilm 
formation, in organisms such as E. coli O157:H7, Salmonella typhimurium and Pseudomonas 
aeruginosa (Brözel et al., 1995).  
Although the development of antibiofilm surfaces is an exciting approach to biofilm treatment it 
is also important to consider alternatives for those infections which are unable to be treated in 
this way. For example, the use of bacteriophages. Bacteriophages were originally discovered by 
Ernest Hanbury Hankin in the late 1800s (Abedon et al., 2011), and the potential of these 
bacterial antagonists in treating human disease was almost immediately recognized and have 
been used to treat a range of bacterial diseases (Davies et al., 2010). Bacteriophages have been 
found to generate polysaccharide lyases capable of depolymerising the biofilm 
exopolysaccharide matrix (Maszewska, A, 2015). Following degradation of the matrix, the 
destruction of the bacteria within is the same process seen in planktonic cells. i.e. the phage 
infects the host bacterium, the nucleic acid is delivered into the cell and the phage DNA or RNA 
is then transcribed within the host cell by hijacking the host machinery, and the phage is 
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reproduced quickly and in high numbers (Kawa et al., 2012). The new phages then lyse the cell 
and are released, resulting in host cell death and further infection of host cells (Azeredo and 
Sutherland, 2008, Beckmann et al., 2005). This method of bacteriophage infection has only so 
far been used in cystic fibrosis patients against Pseudomonas aeruginosa biofilms, but could 
potentially be adapted to tackle infection with medical devices, and also be modified genetically 
to target a wider range of bacterial species (Beckmann et al., 2005, Hughes et al., 1998).  
However, bacteria have evolved a diverse repertoire of phage defence mechanisms, including 
both innate defence systems and, the more recently discovered, CRISPR RNA-guided adaptive 
immune systems (Sorek R., 2013). Despite this, the development of CRISPR-mediated immune 
systems has not eradicated phages, suggesting that viruses have evolved mechanisms to subvert 
CRISPR-mediated protection (Wiedenheft B., 2013). Recently, Bondy-Denomy and colleagues 
(2013) discovered several phage-encoded anti-CRISPR proteins that may prove valuable in 
augmenting phage therapy by enabling targeted suppression bacterial immune systems. 
Whilst the use of naturally-occurring phages to treat bacterial infection has been controversial, 
phage-based antimicrobials has advanced well beyond traditional methods (Lin et al., 2017). 
Novel technologies such as bioengineered chimeras of phage-derived lytic proteins show 
potential as a new class of antibacterial pharmaceuticals (Lin et al., 2017), specifically against 
multidrug-resistant bacterial infections. Suggesting phage therapy has the potential to be used as 
either an alternative or a supplement to antibiotic treatments. 
 
1.5 Research objectives 
Despite obvious advances in the area of biofilm prevention and eradication, the current 
strategies are not entirely effective (del Pozo and Patel, 2007). This leaves a significant amount 
of development needed in the area of antibiofilm coatings and antibiofilm strategies in general, 
specifically for medical implants. This work aims to tackle the increasing problem of biofilm 
infections on medical devices in collaboration with nine other research institutes, SMEs and 
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companies. Using a combinatorial approach the consortium aims to develop a new generation of 
medical implant surfaces/coatings, containing novel antibiofilm molecules (ABMs), such as 
peptides (COATIM, 2012). Studies that were carried out as a member of this partnership 
screened a number of antibiofilm molecules (provided by partners of the consortium) for 
activity against staphylococci and established their mode of action in S. aureus. The top five 
ABMs were then attached onto a porous titanium layer, which would ultimately be used coat 
dental and orthopaedic implants. Next the ABM coated implants were evaluated for in vitro 
activity against resisting microbial biofilm infections, without effecting osseointegration. 
Separately, the ABMs were screened by other members of the consortium for activity against 
different species of bacteria and fungi, in vivo activity of the ABM coated titanium surface, 
ABM toxicity, and for the feasibility of upscaling the production of the ABM coated implants.  
In addition, this study aimed to identify antibiotic adjuvants for currently available antibiotics 
ciprofloxacin and rifampicin against S. aureus biofilms, and rifampicin, fusidic acid or linezolid 
against planktonic E. coli. Screening will use collections of compounds that have either been 
previously FDA-approved for a different indication or have had some existing pre-clinical 
analysis. Any potential combinations were then analysed for their spectrum of antibacterial 
activity the ESKAPE pathogens. 
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Chapter 2  
Materials and Methods 
2.1 Bacterial strains, growth media and growth conditions 
Bacterial and fungal strains used in this study are described in Table 2.1. Staphylococci were 
routinely grown in Mueller-Hinton broth (MHB) or Mueller-Hinton agar (MHA) (Oxoid), with 
the exception of biofilms grown in NuncTM MicrowellTM 96-well microplates, which were 
grown in Tryptic Soy Broth (TSB), and for the evaluation of surface-immobilised antibiofilm 
compounds, cultures were grown in Luria-Bertani broth (LBB) (Oxoid). For studies with 
daptomycin, 183.42 µg/mL CaCl2 was added to culture media. LBB or Luria-Bertani agar 
(LBA) (Oxoid) was used for culturing Escherichia coli (E. coli) and Pseudomonas aeruginosa 
(P. aeruginosa). Candida albicans (C. albicans) were cultured in Yeast Extract-Peptone-
Dextrose (YPD) medium or Roswell Park Memorial Institute (RPMI) medium. All organisms 
were grown at 37 °C with aeration, with the exception of C. albicans which was grown at 30 °C. 
Table 2.1 Bacterial and fungal strains used in this study.0-1 Bacterial and fungal strains used in  
Strain Comments Reference/Source 
Acinetobacter baumanni   
Cubist 581217 NDM-1 Gift from Cubist 
Candida albicans   
ATCC MYA-2876 Human clinical isolate (Fonzi and Irwin, 
1993) 
Enterobacter cloacae   
Cubist 583750 CTX-M-15, ACT/MIR, NDM-1, OXA-48 Gift from Cubist 
   
Escherichia coli   
1411 K-12 strain (O'Neill et al., 
2002) 
MG1655 K-12 strain (Xiao et al., 1991) 
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Table 2.1 (continued) Bacterial and fungal strains used in this study. 
 
Strain Comments Reference/Source 
Escherichia coli   
TG1 K-12 strain (Biriukova et al., 
2010) 
Cubist 449334 CTX-M-15, IMP-1 Gift from Cubist 
Cubist 449742 CTX-M-15, TEM-52 Gift from Cubist 
Cubist 586030 CTX-M-15, CMY-2, NDM-4 Gift from Cubist 
Cubist 605879 CTX-M-15, NDM-6 Gift from Cubist 
Cubist 657524 CTX-M-32 Gift from Cubist 
Cubist IHMA 659048 KPC-2, CTX-M-15, AmpC, CMY+ Gift from Cubist 
Cubist IHMA 684850 KPC-2, SHV-12 Gift from Cubist 
Cubist 702452 CTX-M-97 Gift from Cubist 
Klebsiella oxytoca   
Cubist 683079 CTX-M-14b Gift from Cubist 
Klebsiella pneumoniae   
Cubist 581436 CTX-M-15, CMY-2, DHA, NDM-1 Gift from Cubist 
Pseudomonas aeruginosa   
PA01 Clinical isolate (Stover et al., 2000) 
PA14 Clinical isolate (Rahme et al., 1995) 
Staphylococcus aureus   
SH1000  Derivative of strain 8325-4, with repaired 
defect in rsbU 
(Horsburgh et al., 
2002) 
UAMS-1 Methicillin-sensitive clinical strain. 
Proficient biofilm former 
(Gillaspy et al., 
1995) 
USA3000 Community acquired MRSA  (Tenover and 
Goering, 2009) 
Cubist ACC A790662 Human clinical isolate Gift from Cubist 
ATCC6538 Human clinical isolate (Connolly et al., 
1994) 
Staphylococcus 
epidermidis 
  
ATCC 35984 Proficient biofilm former  (Ryder et al., 2012) 
18 
 
 
2.2 Antimicrobial compounds, reagents and chemicals 
All antibiotics and chemicals used in this study were from Sigma-Aldrich (Poole, UK), with the 
exception of P1a-PEP1, P2-5, CIM008405 and 4-45 (COATIM), Tocris 2611 and Tocriscreen 
Total (Tocris Biosciences, Bristol, UK), vancomycin (Dchefa Biochemie, Haarlem, The 
Netherlands), nisin (NBS biologicals, Cambridgeshire, UK), XF-73 (Destiny Pharma, Brighton, 
UK), National Institute of Health (NIH) clinical collection (NIH, Maryland, USA), Spectrum 
Collection (Microsource Discovery System Inc, Gaylordsville, USA), Live/Dead BacLightTM kit 
and Disc3(5) (Invitrogen, Paisley, UK), the radiolabelled chemicals [methyl-3H]thymidine (70–
95 Ci/mmol), [5,6-3H]uridine (31–56 Ci/mmol) and L-[G-3H]glutamine (20 –50 Ci/mmol) 
(Perkin Elmer, Cambridge, UK), defibrinated equine blood (Oxoid Ltd, Cambridge, UK), 
human plasma and foetal bovine serum (Sera laboratories International, West Sussex, UK). 
Daptomycin was a gift from Cubist Pharmaceuticals (Lexington, MA, USA). Phospholipids 
were purchased from Avanti Polar Lipids. Table 2.2 shows all antimicrobial agents used in this 
study, along with their solvents. 
 Table 2.2 Antimicrobial agents and their solvents used in this study. SDS: sodium dodecyl 
sulphate. dH20: deionised water. 
-2 Antimicrobial agents and their solvents used in this study 
Antimicrobial compound Solvent 
Ampicillin dH20 
Ciprofloxacin 20 mM HCl 
CIM008405 DMSO 
Daptomycin dH20 (+ 183.42 µg/mL CaCl2) 
Fusidic Acid 50% ethanol 
Gentamicin dH2O 
Linezolid DMSO 
Nisin 20 mM HCl 
P1a-PEP1 dH20 
P2-5 dH20 
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Table 2.2 (continued) Antimicrobial agents and their solvents used in this study. SDS: sodium 
dodecyl sulphate. dH20: deionised water. 
 
Antimicrobial compound Solvent 
Rifampicin DMSO 
SDS dH20 
Tetracycline dH20 
Tocris 2611 DMSO 
Vancomycin dH20 
XF-73 dH20 
4-45 DMSO 
 
2.3 Antimicrobial susceptibility determinations 
Antibiotic minimum inhibitory concentrations (MICs) were determined using 2-fold serial 
dilutions of antibiotic in MHB according to the Clinical Laboratory Standards Institute (CLSI) 
guidelines (Cockerill et al., 2012). Overnight cultures were added to the antibacterial agent at an 
inoculum of 5 x 105 CFU/mL, and incubated for 18-24 hours at 37 °C. The MIC was identified 
as the lowest concentration of drug which inhibited visible bacterial growth. 
Biofilm MICs (bMICs) and minimum biofilm eradication concentrations (MBECs) were 
determined using the Calgary Biofilm Device (CBD) (Nunc) as described previously (Ceri et 
al., 1999). Overnight cultures were diluted 1/100 in fresh MHB, and incubated with pins of the 
CBD for 24 hours at 37 °C. CBD grown biofilms can reach an innoculum of ~107 CFU/peg. The 
bMIC was identified as the lowest concentration of drug at which no bacterial growth was 
observed. For MBEC determination, the pegs from the bMIC were washed twice in saline 
solution and immersed in wells containing drug free MHB and incubated for 24 hours at 37 °C. 
The MBEC was identified at the concentration of antibacterial agent that resulted in complete 
eradication of the biofilm. As biofilms grown on the CBD are limited for more in depth studies, 
a second biofilm model was used in which biofilms were grown in the wells of 96-well plates. 
To aid biofilm growth, 20 % human plasma in 0.05 M carbonate buffer was added to the wells 
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and incubated at 4 °C overnight. Human plasma was then removed prior to addition of S. aureus 
(1/100 in TSB) before further incubation for 24 hours at 37 °C. Biofilms were washed once in 
saline solution and exposed to antibacterial agent in fresh MHB. Cultures were maintained at 37 
°C for 24 hours. Biofilms were washed once in saline solution and incubated with proteinase K 
(100 µg/mL in 20 mM tris and 100 mM NaCl, pH 7.5) for 1 hour. Dispersed biofilm cells were 
collected, washed and resuspended in PBS then cultured on MHA and incubated at 37 °C 
overnight for viable counting. The MBEC was determined as the lowest concentration of 
antimicrobial drug that prevented the recovery of viable cells.  
 
2.4 Time-dependent killing studies 
Standard time-kill methodology was used to study the killing kinetics of Tocris 2611 and 
comparator agents against early exponential-phase cultures of SH1000 as previously described 
(Ooi et al., 2009, Randall et al., 2013b). Briefly, bacteria were incubated at  37 °C to optical 
density (OD)600 of 0.2, exposed to either 4 x MIC of comparator agent or 0.5, 8 and 64 µg/mL 
of Tocris 2611 (4 xMIC, CBD MBEC and 96-well plate MBEC, respectively). Aliquots of 
culture were taken regularly over 24 hours for determination of viable counts. 
Viable counts were determined over the course of 24 hours by diluting in PBS as necessary, 
culturing onto MHA, and incubating for 18-24 hours at 37 °C.  
Time-kills against stationary phase SH1000, were performed as described, except overnight 
cultures were centrifuged at 5500 rpm for 10 minutes at 37 °C and resuspended in supernatant 
to OD600 of 0.2 before being exposed to antibacterial agents. Persister time-kills were performed 
according to previously described methodology (Keren et al., 2004, Wiuff et al., 2005). Briefly, 
bacterial cultures were incubated to early exponential phase (OD600 of 0.2). To half of the 
culture 10 x MIC ciprofloxacin was added, and to the other, 10 x MIC ampicillin was added and 
cultures were incubated at 37 °C for 24 hours. After 24 hours, remaining viable cells were 
collected by centrifugation, washed, and resuspended to the same volume in MHB and exposed 
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to antibacterial agents at 37 °C. Aliquots of culture were taken regularly over 24 hours for 
determination of viable counts. 
 
2.5 Identification of antibiotic adjuvants from chemical libraries 
Three compound libraries of biologically active small molecules were evaluated for antibiotic 
adjuvants; the NIH Clinical Collection (727 compounds), Tocriscreen Total collection (1120 
compounds), and the Spectrum Collection (2320 compounds). All library compounds were 
supplied pre-dissolved in DMSO at a concentration of 10 mM. Duplicates of each library were 
made at 1 mM and individually screened in combination with clinically available antibiotics 
ciprofloxacin or rifampicin against S. aureus SH1000 biofilms, or rifampicin, linezolid or 
fusidic acid against planktonic cultures of E. coli 1411. All screens were performed in 96-well 
plates and library compounds were tested at 10 µM. 
S. aureus biofilms were grown in 96-well plates as described in section 2.3. After 24 hours 
growth, biofilms were washed once in saline solution and exposed to 198 µL of MHB 
containing either 50 µg/mL ciprofloxacin or rifampicin, before 2 µL aliquots of library 
compounds were added to a final concentration of 10 µM and incubated for 24 hours at 37 °C. 
Biofilms were washed once in saline solution and stained with 200 µL 10 % crystal violet 
solution for 30 minutes. Biofilms were washed twice more in deionised water and antibiofilm 
activity was determined as loss or eradication of the biofilm visualised by crystal violet staining. 
Planktonic cultures of E. coli were tested according to CLSI guidelines for broth MICs (section 
2.3) with the exception that antibacterial agent rifampicin was tested at fixed concentration 0.5 
µg/mL, whilst linezolid and fusidic acid were tested at 50 µg/mL. As before, library compounds 
were tested at a final concentration of 10 µM. Activity was identified in the same way as broth 
MIC’s; inhibition of bacterial growth. 
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2.6 Identification of synergistic interactions 
Combinations of antibacterial agents were assessed for synergistic interactions against 
planktonic cultures of E. coli, following the checkerboard methodology (Pillai et al., 2005). The 
following equation was used to calculate the fractional inhibitory concentration (FIC) index:  
                  ⎟
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A FIC index of <0.5 is considered a synergistic interaction, an index of 1 is taken to indicate an 
additive interaction, whilst >2 is an antagonistic interaction. 
 
2.7 Antibacterial mode of action studies 
2.7.1 Macromolecular synthesis assay 
Alterations in macromolecular synthesis as a consequence of exposure to Tocris 2611 and 
comparator agents was investigated by quantifying incorporation of radiolabelled precursors 
into DNA ([methyl-3H]thymidine), RNA ([5,6-3H]uridine) and protein (L-[G-3H]glutamine), in 
early exponential-phase cultures of S. aureus SH1000 in MHB (culture absorbance 0.2 units at 
600 nm; ∼108 cfu/mL) (Cherrington et al., 1990). At culture OD, precursors were added to 
1µCi/ml and incubated at 37 °C. After incubation for 10 minutes, 100 µL of each radiolabeled 
culture was mixed with 100 µL of ice-cold 10 % trichloroacetic acid (TCA) and stored on ice. 
Remaining cultures were treated with 4 x MIC antibacterial agents. After 10 minutes incubation, 
100 µL of the cultures were mixed with an equal amount of 10 % TCA and kept on ice for 30 
minutes. TCA precipitates were collected under vacuum using UniFilter GF/B plates (Perkin-
Elmer), and filters onto which [5,6-3H]uridine-labelled samples had been deposited were 
washed twice with 100 µL unlabeled uridine. Individual filters were then washed twice with 200 
µL of 10 % TCA, and twice with 200 µL of acetic acid (Hilliard et al., 1999). Filter plates were 
dried, and 25 µL scintillant (Microscint 20, Perking-Elmer) was added to each well, and 
radioactivity was measured using a Chameleon multilabel plate scintillation counter (Hidex).  
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2.7.2 BacLightTM assay 
The BacLightTM assay was used to measure staphylococcal membrane integrity following 
exposure to antimicrobial agents at 4 x MIC. S. aureus SH1000 was grown to OD600 0.5-0.6 
(Hilliard et al., 1999, Ooi et al., 2013). Cells were harvested, washed in sterile deionised water 
and resuspended to double the original volume. Compounds were added at 4 x MIC, with the 
exception of SDS which was used as a 5 % (w/v) solution, and incubated at 37 °C for 10 
minutes. Cells were washed twice in sterile deionised water and resuspended to equal volumes. 
50 µL of suspensions were dispensed to individual wells of a black 96-well plate (Greiner Bio-
One). In the dark, 150 µL of BacLightTM reagent was added to the wells and incubated for 15 
minutes at room temperature. Red (emission 620-650 nm) and green (emission 510-540 nm) 
fluorescence were measured using a FLUOstar Omega (BMG Labtech) plate reader (excitation 
wavelength of 470nm). The red : green fluorescence ratio was calculated and percentage 
membrane integrity relative to cells treated with 5% (w/v) SDS was calculated. If membrane 
integrity was <70%, compounds were considered membrane damaging. 
2.7.3 DiSC3(5) assay 
The membrane potential of staphylococci exposed to antimicrobial agents was determined using 
the fluorescent dye DiSC3(5) as previously described (Hobbs et al., 2008). Cultures of SH1000 
cells were grown to OD600 0.2, washed twice, and resuspended in 5 mM HEPES and 5 mM 
glucose buffer (pH 7.2). In the absence of light, 100 mM KCl and 2 µM DiSC3(5) were 
incubated with cells at 37 °C for 30 minutes to allow the dye to be taken up. Cultures were then 
exposed to antibacterial agents at 4x MIC. At necessary time points, samples were taken and 
processed as follows; centrifugation to collect cells, followed by 1 mL of supernatant added to 1 
mL DMSO. A further 1 mL DMSO was added to the remaining pellet to lyse the cells. After 10 
minutes incubation, 1 mL of lysed sample was mixed with 1 mL of HEPES/glucose buffer (pH 
7.2). Extracellular and intracellular fluorescence were read on the LS 45 luminescence 
spectrometer (Perkin-Elmer) at an excitation of 622 nm and an emission of 670 nm. The Nernst 
equation (Silverman et al., 2001) was used to calculate membrane potential;  
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    Δ  = − !"!  In !"#$! !  !"#!$% !"#$! ! !"#$%&'    
 
 Δ  is the membrane potential, R is the universal gas constant (8.3144598 J mol−1 K−1), T is the 
absolute temperature and F is the Faraday constant (96485.33289 Coulomb mol−1).  
2.7.4 Liposome integrity 
Carboxyfluorescein (CF) loaded liposomes matching the lipid composition of staphylococcal 
(60% [wt/wt] phosphatidylglycerol, 40% cardiolipin) or mammalian (50% phosphatic acid 
[wt/wt], 50% phosphatidylcholine) cytoplasmic membranes were prepared and tested as 
previously described (Randall et al., 2013a, StGelais et al., 2007). Briefly, lipid mix was pre-
dried using non-oxygen gas Argon, and further dried for two hours under vacuum. The dried 
lipid mix was resuspended at room temperature and vortexed thoroughly. Homogenised lipids 
were then extruded at 37°C and ultracentrifuged at 100000g for 15min (three times). The 
following equation was used to determine liposomes were intact and measure liposome 
concentration (mM) at OD570; 
 2.75mM (average lipid molarity)OD!"# pre extrution sample ∗ dilution (1: 10) ∗ OD!"# liposomes 
 
For the assay itself, 50 µM of liposomes were treated with compounds at 4 x MIC and leakage 
of carboxyfluorescein was monitored over 3 hours by measuring flourescence.  Percent 
liposome integrity was calculated relative to the positive control, 0.5% Triton X-100. 
Fluorescence was measured at excitation 485 nm and emission 520 m, in fluorescence 
microtitre plates (Greiner Bio-One) using the FLUOstar Omega (BMG Labtech). 
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2.7.5 Haemolysis assay 
Haemolysis of equine erythrocytes was measured to evaluate the ability of compounds to 
damage mammalian membranes (Ooi et al., 2013, Oliva et al., 2003). Compounds were tested at 
4 x MIC. Whole blood containing lithium heparin was centrifuged at 1000 x g for 10 minutes, at 
4 °C. The supernatant was removed from the buffy coat and erythrocytes were washed three 
times in 1/20 10 mM Tris-HCl, 0.9% NaCl, pH 7.4 (kept at 4 °C). Erythrocytes were diluted 
1/25 in buffer and before use were incubated at 37 °C for 15 minutes. Compounds and 
erythrocytes were incubated for 1 hour at 37 °C before being centrifuged at 3000 x g for 5 
minutes. Haemolysis was measured at OD540 and expressed as a percentage relative to the 
positive control (5 % SDS). 
2.7.6 Selection of Tocris 2611 resistant mutants 
Mutational resistance of S. aureus to Tocris 2611 and control agent rifampicin was initially 
determined by assessing spontaneous mutation frequencies (Ryder et al., 2012, O'Neill et al., 
2001).  Overnight cultures of S. aureus SH1000 were plated onto MHA containing 4 x MIC of 
antibacterial agent and incubated for 48 hours at 37 °C. Mutation frequencies were determined 
as the number of drug resistant colonies as a percentage of the total population determined on 
drug-free MHA. 
Exposure to Tocris 2611 did not cause resistance from spontaneous mutation. Therefore, an 
alternative protocol for resistance selection was used; the extended gradient MIC (Randall et al., 
2013b, Friedman et al., 2006). Cultures of SH1000 were continuously exposed to an extended 
concentration range of Tocris 2611 and control agent daptomycin over 25 passages. 
Methodology was carried out in accordance with the methodology for broth MICs (Section 2.3), 
with the exception that cultures were exposed to a wider range of concentrations within the 
dilution series. Each new passage was inoculated by the cells which grew at the highest 
concentration of antibacterial agent in the preceding passage.  
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2.8 Quantification of biofilm material  
To determine the effect of Tocris 2611 on biofilm structure, the proportion of matrix and cells 
present after 6 or 24 hours exposure to Tocris 2611 was quantified. Biofilms were grown and 
exposed to antibacterial agents using the 96-well plate format (Section 2.3). Proteinase K was 
added at 100 µg/mL in 20 mM tris and 100 mM NaCl, pH 7.5. Tocris 2611 was tested at 0.5, 8 
and 64 µg/mL (4 x MIC, CBD MBEC, and well MBEC, respectively). After 6 or 24 hours 
biofilms were washed in deionised water and stained in the dark for 30 minutes with SYPRO® 
Ruby containing 0.167 µM SYTO® 9. Biofilms were washed again in deionised water and 
fluoresence was read using the FLUOstar Omega (BMG Labtech) at an excitation of 480 nm 
and emission of 620 nm (matrix) and 520 nm (cells). Red : green fluorescence ratios were 
calculated to determine matrix : cell ratio.  
 
2.9 Analysis of surface immobilised antibiofilm molecules 
2.9.1 In vitro activity analysis of antibiofilm compounds immobilised on smooth titanium 
surfaces 
P. aeruginosa PA14, E. coli TG1 and S. aureus (ATCC6538 or SH1000) were cultured 
overnight in LBB at 37 °C. Simultaneously, smooth titanium disks were incubated overnight in 
foetal bovine serum at 37 °C. Disks were washed once in PBS and transferred to wells of a 96-
well plate. 200 µL of overnight culture of P. aeruginosa or E. coli diluted 1/100 in 1/20 TSB, or 
S. aureus diluted 1/100 in LBB were added to disks and incubated for 24 hours at 37 °C. Disks 
were individually washed once in PBS and transferred to a fresh 1 mL PBS, before being 
vigorously vortexed for 1 minute, sonicated for 10 minutes and vortexed again for 1 minute to 
remove adherent biofilms. Serial dilutions in PBS were then made to quantify biofilm formation 
on the disks, before plating onto MHA and incubating for 18-24 hours at 37 °C. Biofilm 
inhibition was calculated by enumerating colonies and expressing as a percentage of the 
negative control (compound free disks).  
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2.9.2 In vitro activity analysis of antibiofilm compounds immobilised on open porous 
titanium surfaces 
Antibiofilm activity of antibacterial compounds immobilised to open porous titanium disks were 
analysed using the same methodology described in section 2.9.2 with the following exceptions; 
instead of using a 96-well plate, disks were wrapped in parafilm and silicone tubing (VWR 
International) leaving only the drug coated side of the disk exposed. Parafilm and silicone 
tubing were previously sterilized using 70 % ethanol.  Overnight bacterial cultures were diluted 
1/10000 in 1/20 TSB and 200 µL was added to the surface of the disk, before being incubated 
for 24 hours at 37 °C. In sterile conditions, disks were removed from the parafilm and silicone 
tubing before being washed, vortexed and enumerated as before (Section 2.9.2). 
 
2.10 DNA manipulation 
2.10.1 Genomic DNA extraction 
Preparation of high-purity genomic DNA from S. aureus was carried out using the PurElute™ 
bacterial genomic kit (EdgeBio, Maryland, USA) following manufacturer’s instructions, with 
the following additions; spheroplast buffer was supplemented with 100 µg/ml lysostaphin and 
cells incubated for 60 minutes at 37 °C, and a 15 minute incubation with 100 µg/ml of 
proteinase K at 37 °C was included before the addition of Advamax 2 beads. Whole genome 
sequencing and bioinformatic analysis was carried out by the Leeds Institute of Molecular 
Medicine, University of Leeds. 
2.10.2 Polymerase chain reaction (PCR) 
Phusion® High-Fidelity DNA Polymerase (New England Biolabs, Massachusetts, USA) was 
used to amplify genomic DNA according to manufacturer’s instructions. All primers were 
synthesised by Eurofins MWG Operon and reaction conditions followed those suggested by the 
manufacturer. PCR products were purified using QIAquick PCR Purification Kit (QIAGEN, 
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Manchester, UK) according to manufacturer’s instructions and sequenced by Beckman Coulter 
Genomics (Essex, UK). Oligonucleotide primers are listed in Appendix A. 
2.10.3 Agarose gel electrophoresis 
Amplified PCR products were visualised by agarose gel electrophoresis (Sambrook and Russell, 
2001). Gels were 0.8% (w/v) agarose dissolved in Tris-acetate-EDTA (TAE) buffer containing 
1:10000 SYBR® safe gel stain (Invitrogen, ThermoFisher Scientific, Massachusetts, USA). To 
determine the molecular weight of the analysed PCR product, either DNA Hyperladder I or II 
(Bioline Reagents) were run alongside the sample. A potential difference of 90 V was applied 
across the gel for 30 minutes. DNA was visualised using a Syngene, Genegenius Bioimaging 
gel documentation system. 
2.10.4 DNA quantification 
To determine DNA concentration, the absorbance of samples was read using Nanophotometer® 
(Geneflow, Lichfield, UK), at 260 nm. The ratio of absorbance values at 260 nm : 230 nm and 
260 nm : 280 nm reported on sample purity. A 1.8 ratio reflected a pure sample (Desjardins and 
Conklin, 2010) .  
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Chapter 3 
Development of antibiofilm compounds for medical 
implants 
3.1 Abstract 
Biofilm associated infections are responsible for ~25% of medical device implant (MDI) 
failures. The most recent generation of MDIs with open porosity facilitate osseointegration, but 
also present increased risk of biofilm formation as bacteria preferentially adhere to surfaces 
such as these. This work therefore aimed to identify and characterise five novel ABMs, for 
development as dental and orthopaedic implants coatings. The activity and potential toxicity of 
56 novel ABMs was assessed and the best five were identified: 4-45, CIM008405, P1a-PEP1, 
P2-5 and Tocris 2611. P1a-PEP1 and P2-5 were most effective against fungal pathogens, whilst 
4-45, CIM008405 and Tocris 2611 exhibited more potent activity against bacterial pathogens. 
Tocris 2611 was the only ABM to possess the ability to eradicate preformed staphylococcal 
biofilms and its MOA is consequently discussed in Chapter 4 instead. Since the preclinical 
evaluation of new drugs includes MOA studies, initial experiments investigated whether the 
antibacterial activity of the ABMs was through inhitition of one of the major macromolecular 
synthesis pathways (DNA, RNA or protein). None of the four ABMs (4-45, CIM008405, P1a-
PEP1, P2-5) caused preferential inhibition any of the specific pathways tested, instead targeting 
the bacterial membrane, resulting in damage and loss of potential. All four ABMs caused 
destruction of staphylococcal and mammalian liposomes, aswell as complete or near complete 
lysis of equine erythrocytes, indicating a direct interaction with the phospholipid bilayer, and a 
lack of prokaryotic specificity. In vitro testing of the five ABMs attached to smooth and open 
porous surfaces impacted biofilm formation, but had no effect on biofilm formation in vivo. 
Despite this, work presented here successfully developed a useful approach to implant coatings. 
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3.2 Introduction 
Biofilm formation is estimated to be involved in 80% of all bacterial infections in humans and 
biofilm-related corrective surgery costs in Europe are estimated at €15,000 per patient and €800 
million per year (Davies, 2003, Fux et al., 2005). Medical implants that require rapid 
osseointegration, such as joint prostheses, have been developed to include porous surfaces, 
which further increases the risk of biofilm related infections due to enhanced bacterial 
attachment. Alternative treatment approaches to prevention are therefore crucial. One such 
alternative approach is the development of antibiofilm surfaces to cover indwelling medical 
devices. To reduce biofilm-associated infections on implants, biocidal coatings can be applied 
based on the use of metal ions like silver, which is toxic when accumulated, or the release of 
conventional antibiotics to prevent infection at the site of the implant. A serious concern 
regarding such continuous antibiotic pressure however is an increased incidence of clinical drug 
resistance, such as observed for the methicillin-resistant Staphylococcus aureus (MRSA). In this 
respect, the development of antibiotic resistant infections can lead to devastating effects in the 
absence of any valid medical treatment to control the infection, and has become a serious public 
health problem. Another important challenge of biocidal implant coatings is to achieve 
antimicrobial activity without impairing osseointegration caused by general cytotoxicity. 
It is therefore important to elucidate the mechanism of action of compounds for clinical 
applications such as these. To determine a compound’s MOA there are a wide variety of 
experiments that can be performed.  For the work described in this chapter, studies to identify 
an agents cellular target were initially performed, by measuring alterations in macromolecular 
synthesis (MMS) pathways (DNA, RNA and protein) as a consequence of exposure to the 
compound. Although not performed in the following sections, initial MOA studies could also 
include, but are not limited to, bacterial cytological profiling and the use of whole-cell B. 
subtilis biosensors. 
This work therefore aims to develop antibiofilm coatings on porous titanium layers coated 
implant material using novel small molecules and peptides with inhibitory activity against 
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microbial biofilms, which are associated with partners of this project (COATIM). Research 
focuses on implant coatings that do not release the antibiofilm compounds, representing longer-
lasting antibiofilm and topical activity. In addition, studies will assess the effects of the ABMs 
on osseointegration, aswell as characterise the MOA of the top five ABMs. 
 
3.3 Aims and objectives 
Work described in this chapter was intended to identify five novel antibiofilm molecules 
(ABMs), elucidate their mode of action (MOA) against S. aureus and assess their ability to 
prevent biofilm formation when immobilised to a titanium surface. This work was performed as 
part of an EU consortium, collectively known as COATIM. COATIM involves the 
collaboration of four SME’s, one company, and three universities aiming to develop the next 
generation of antibiofilm coatings for medical implants. 
 
3.3 Results and Discussion 
3.3.1 Identification of the five top novel antibiofilm molecules 
 
In COATIM, 56 ABMs (identified in previous drug screening programs conducted by the 
partners) were assessed in order to determine the best five. These molecules were selected for 
inhibitory activity against bacterial and/or fungal biofilms (either inhibiting their formation or 
eradicating biofilms including persisters). The five ABMs were selected based on their ability to 
inhibit biofilm formation of different bacterial and fungal species, toxicity against nematodes, 
and toxicity profiles for different human primary cell types, which are relevant for implant 
fixation. In parallel, a biofilm mouse colonization model was developed and the mode of action 
of these ABMs was unraveled. Finally, the ABM-coated implants were evaluated for in vitro 
and in vivo activity in resisting microbial infection without compromising osseointegration. The 
work presented here, performed as a member of the COATIM consortium, focuses on 
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characterization of the five best ABMs, in the Gram-positive organism Staphylococcus aureus; 
the leading cause of post-operative infections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 ABMs screened for activity against biofilms of S. 
epidermidis, S. aureus, S. mutans, P. aeruginosa, C. 
albicans, E. coli and S. typhimurium.  
 
56 ABMs tested for non-toxicity of the multicellular 
nematode worm C. elegans 
 
Based on these data, the following 25 ABMs were selected for further testing: 
 
Antifungal agents  Antibacterial agents 
- 8339         -    202611 
- 27458         -    4-49 
- 42170         -    4-32 
- P2-1         -    4-122 
- P2-5         -    5-21 
- P2-8         -    5-59 
- P2-14         -    5-102 
- P1a-PEP1        -    P1a-CIM02 
- OSIP10         -    P1a-PEP7 
                  -    CIM006387 
           -   CIM006387 
        -    CIM007844 
        -    CIM008405 
        -    CIM003592 
        -    BCF-AA022 
        -    BCF-AA045 
The ability of the 25 ABMs to 
prevent biofilm formation of P. 
gingivalis and polymicrobial biofilms 
was determined.  
The effects of the ABMs on cell 
viability, and functional behaviour 
(differentiation potential) were tested, to 
determine that they are not cytotoxic for 
bone tissue and do not negatively effect 
osseointegrative potential of the implant. 
 
The 25 ABMs were tested for their 
remaining activity upon gamma-
irradiation (the technique which will be 
used to sterilize the implants). 
Based on these results, the following 5 ABMs were selected: 
 
Antifungal agents                  Antibacterial agents 
 
- P2-5           -   202611 
- P1a-PEP1          -    4-45 
                          -  CIM008405 
Mode of action studies of the top 5 ABMs 
(including propensity of microbials to 
develop resistance to the agents). 
In vitro activity of ABM-coated 
smooth and open porous disks.  
In vivo activity of ABM-coated 
smooth and open porous disks.  
All 5 ABMs are found to be 
membrane damaging agents. 
ABMs coated on smooth disks 
exhibited stronger antimicrobial 
activity than on open pourous 
disks. 
None of the ABMs exhibited in 
vivo antibiofilm activity. 
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Figure 3.1 A selection of 56 antibiofilm molecules (ABMs) were screened for antibacterial and 
antifingal activity, aswell as cytotoxicity. Based on these results, the top five ABMS were 
grafted on small titanium implant substrates, as a model for dental and orthopaedic implants. 
Next, the ABM-coated implants were evaluated for in vitro and in vivo activity in resisting 
microbial infection without compromising osseointegration. In parallel, the antibiofilm mode of 
action of the ABMs was unraveled. This work aimed to develop the next generation of implant 
coatings containing novel potent proprietary antibiofilm molecules (ABMs) with inhibitory 
activity against microbial biofilms. 
 
3.3.1.2 Susceptibility of monospecies staphylococcal strains to novel antibiofiolm molecules 
The susceptibility of three different S. aureus strains were used: SH1000, UAMS-1 and 
USA300, and one strain of S. epidermidis: RP62A, was determined against the 56 novel 
antimicrobial agents (Appendix B).  SH1000 is a strain extensively studied because it forms 
robust biofilms in vitro (Geoghegan et al., 2010). It has a repaired defect in rsbU, which 
encodes a positive regulator of the alternative sigma factor Sigma(B), which positively increases 
biofilm formation (Jonsson et al., 2004). UAMS-1 is a widely used MSSA strain that was 
isolated from an osteomyelitic patient, and is a prolific biofilm former (Gillaspy et al., 1995). 
USA300, which is the most prevalent community acquired MRSA strain. RP62A, a commonly 
used reference strain, is also biofilm producing and was isolated during the 1979 to 1980 
Memphis, Tennessee, outbreak of catheter-associated sepsis (Christensen et al., 1987). In terms 
of in vitro biofilm composition, SH1000 and UAMS-1 biofilms are polysaccharide dominant 
(Beenken et al., 2004), and USA300 is a protein adhesion type (Pozzi., 2012). Whilst biofilm 
formation in RP62A is PIA-dependent (Izano et al, 2005). All compounds were tested in µM 
(up to 100 µM) to account for the differences in molecular weight. 
Approximately half of compounds tested against planktonic cultures of SH1000, USA300, 
UAMS-1 or RP62A (22 of 56), exhibited no activity (MICs greater than 100 µM) (Appendix B). 
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Most compounds (34 of 56) were unable to inhibit the shedding of cells from the biofilm in all 
four staphylococcal strains, with bMICs greater than 100 µM (Appendix B). Of the remaining 
compounds tested, MICs and bMICs ranged from 6.25-100 µM, with the exception of Tocris 
2611, which exhibited an MIC and bMIC of less than 0.4 µM (Appendix B). By comparison, 
established antibiotics ciprofloxacin and gentamicin exhibited MICs and bMICs ranging from 
6.25-100 µM. With the exception of Tocris 2611, which had MBECs ranging from 6.25 µM to 
12.5 µM, none of the compounds (including control agents ciprofloxacin and gentamicin) were 
able to eradicate pre-formed staphylococcal biofilms (Appendix B).  
Although staphylococci are one of the most common causes of biofilm-related infections, it is 
also important to consider other pathogens frequently associated with these types of infection, 
such Pseudomonas aeruginosa (P. aeruginosa) and Candida albicans (C. albicans). 
Furthermore, agents developed as clinical treatments must exhibit selective toxicity against 
microbial cells. Consequently, all 56 novel ABMs were screened by other members of the 
COATIM consortium, against Streptococcus mutans (S. mutans), Escherichia coli (E. coli), 
Salmonella Typhimurium (S. Typhimurium) P. aeruginosa, Porphyromoas gingivalis (P. 
gingivalis) and C. albicans, and their toxicity was assessed against Caenorhabditis elegans (C. 
elegans). C. elegans is regularly used as toxicity model, since many of the basic physiological 
processes and stress responses that are observed in higher organisms, such as humans, are 
conserved in C. elegans. Accordingly, 14 of 56 compounds were selected for further testing 
based on the potency of their antimicrobial activity and non-toxicity for C. elegans. These were 
4-29, 4-45, 4-122, 5-21, 5-59, 5-102, BS-342, CIM003592, CIM006387, CIM007844, 
CIM008405, P1a-CIM02, P1a-PEP1 and Tocris 2611.  
 
3.3.1.2. Susceptibility of multispecies staphylococcal biofilms to antibiofilm compounds 
In vitro biofilm research is performed predominantly using single species of microorganims, 
despite the fact that the majority of biofilm infections involve polymicrobial communities.   
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Subsequently, pre-formed polymicrobial staphylococcal biofilms of S. aureus USA300 and S. 
epidermidis RP62A were exposed to the 14 ABMs that were selected for further testing (Table 
3.1). Five of the 14 compounds exhibited no inhibition of biofilm shedding, with bMICs greater 
than 100 µM. With the exception of Tocris 2611, bMICs for the remaining 9 compounds ranged 
from 25-100 µM. Tocris 2611 exhibited comparable activity against polymicrobial and 
monospecies biofilms, with a bMIC of < 0.4 µM, and an MBEC of 6.25 µM (Table 3.1). None 
of the other 14 compounds were able to eradicate pre-formed polymicrobial S. aureus and S. 
epidermidis biofilms, with MBECs > 100 µM (Table 3.1). In addition, control agents 
ciprofloxacin and gentamicin were also unable to eradicate an established S. aureus/S. 
epidermidis biofilm, with MBECs greater than 100 µM (Table 3.1).  
The ability of the 14 novel antibiofilm molecules to prevent formation of other multi-species 
biofilms was determined by other COATIM partners. Polymicrobial biofilms tested were C. 
albicans and S. epidermidis, C. albicans and S. aureus, C. albicans and E. coli, and E. coli and 
P. aeruginosa. Furthermore, the effect of the 14 antibiofilm compounds on the three most 
relevant cell types represented in bone tissue (osteoblasts, bone marrow derived stem cells and 
endothelial cells) was also assessed by the COATIM consortium, to determine if the ABMs 
negatively affect the osseointegrative potential of the implant. Cytotoxicity tests were 
determined in these cell types since it is important the antibiofilm molecules to not negatively 
impact the osseointegrative potential of the coated implant, or the surrounding bone tissue. 
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Table 3.1 Antibiofilm activity of novel antibacterials agents and control agents (ciprofloxacin 
and gentamicin) against S. aureus USA300 and S. epidermidis RP62A polymicrobial biofilms. 
ntibiofilm activity of novel antibacterial agents 
 Biofilm minimum inhibitory 
concentration (bMIC) (µM) 
Minimum biofilm eradication 
concentration (MBEC) (µM) 
Antibacterial agent 
S. aureus USA300 and S. 
epidermidis RP62A 
S. aureus USA300 and S. 
epidermidis RP62A 
Ciprofloxacin 100 >100 
Gentamicin 100 >100 
4-29 >100 >100 
4-45 25 >100 
4-122 50 >100 
5-21 25 >100 
5-59 >100 >100 
5-102 >100 >100 
BS-342 >100 >100 
CIM003592 100 >100 
CIM006387 100 >100 
CIM007844 100 >100 
CIM008405 25 >100 
P1a-CIM02 >100 >100 
P1a-PEP7 50 >100 
Tocris 2611 < 0.4 6.25 
 
Based on these parameters, the five best ABMs were selected from the 14 that underwent 
further investigation. These were 4-45, CIM008405, P1a-PEP1, P2-5 and Tocris 2611. 
However, as Tocris 2611 exhibited eradication activity of preformed staphylococcal biofilms, 
its MOA will no longer be presented in this chapter, instead it is presented in Chapter 4.  
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3.3.2 Elucidation of the mode of action of the four antibiofilm molecules 
3.3.2.1 Effects of the four antibiofilm molecules on major macromolecular synthesis 
pathways 
Initial investigations to establish the MOA of the four ABMs (4-45, CIM008405, P1a-PEP1 and 
P2-5) monitored alterations in macromolecular synthesis following exposure to 4 x MIC of 
compound. This was done by quantifying incorporation of radiolabeled precursors into the 
macromolecules DNA, RNA and protein (Hobbs et al., 2008, Ooi et al., 2009, Randall et al., 
2013b). This method is commonly used as it can provide insights into the MOA, especially 
since some antibiotics often exhibit activity which is specific to one macromolecular pathway, 
with little or no effect on other macromolecular biosynthesis pathways (O'Neill and Chopra, 
2004, Ooi et al., 2013, Randall et al., 2013b). 
Against S. aureus, at 4 x MIC, none of the four ABMs caused preferential inhibition of DNA, 
RNA or protein synthesis within 10 minutes (Figure 3.1).  In comparison, control agents 
ciprofloxacin, rifampicin and tetracycline specifically inhibit the synthesis of DNA, RNA, and 
protein, respectively (Figure 3.1). This type of non-specific response is indicative of compounds 
that have antimicrobial activity against S. aureus by disrupting the cytoplasmic membrane 
(O'Neill and Chopra, 2004, Ooi et al., 2009, Randall et al., 2013b). 
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Figure 3.1 Effects of control agents and four ABMs on major macromolecular biosynthesis 
pathways in S. aureus SH1000. Percentage incorporation of H3 thymidine, uridine and 
glutamine into SH1000 DNA, RNA and protein synthesis. Means of at least three independent 
replicates; error bars show standard error. 
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3.3.2.2 Effects of the four antibiofilm molecules determined in membrane damaging assays 
To further assess whether the MOA of the four ABMs is through disruption of the cytoplasmic 
membrane, the BacLightTM assay was used to measure integrity of the S. aureus membrane. 
This method measures membrane integrity using two dyes (SYTO® 9 and propidium iodide). 
Both dyes stain nucleic acid, but propidium iodide can only enter cells which have undergone 
damage to the membrane, whilst SYTO® 9 is able to enter both damaged and undamaged cells. 
The ratio of the dyes is therefore directly proportional to the amount of membrane damage as a 
consequence of exposure to the drug. 
S. aureus cultures were exposed to 4 x MIC of the antibiofilm molecules and control agents 
(tetracycline and nisin) for 10 minutes. Tetracycline is known to inhibit protein synthesis, and to 
have no effect on the bacterial membrane. Nisin is a known membrane damaging compound 
which forms pores in the membrane (McAuliffe et al., 2001). The four antibiofilm molecules 
caused a loss in membrane integrity (Table 3.2); compounds 4-45, CIM008405 and P2-5 
resulted in complete loss of membrane integrity after 10 minutes, comparable to that observed 
for membrane damaging compound nisin (Table 3.2). Whilst S. aureus cells exposed to P1a-
PEP1 and tetracycline, retained 71% and 98 % membrane integrity, respectively (Table 3.2). 
However, compounds that reduce the membrane integrity by > 25% in this assay, are still 
considered to exert their antibacterial effects through membrane disruption. 
The four antibiofilm molecules were then assessed in a second membrane damaging assay, that 
utilize the membrane potential-sensitive fluorescent dye DiSC3(5), and offers a more sensitive 
measure of membrane perturbation. S. aureus cells are hyperpolarised and incubated with 
DiSC3(5), causing the dye to concentrate in the membrane and become self-quenching. 
Subsequent membrane damage causes a loss of membrane potential and release of DiSC3(5), 
which is then measured by fluorescence. All compounds were tested at 4 x MIC and nisin and 
tetracycline were again used as comparator agents.  
All four ABMs caused a rapid loss in membrane potential (Table 3.2). Within 1 hour, there was 
a 100 % reduction in membrane potential of cells exposed to 4-45, CIM008405 and P2-5, a 
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result comparable to that observed for the known membrane damaging agent, nisin (Table 3.2). 
The loss of membrane potential caused by P1a-PEP1 was 57 % after one hour, a less 
pronounced effect than that caused by four other ABMs (Table 3.2). Similarly, a less significant 
effect was observed for P1a-PEP1 in the BacLightTM assay and quantification of 
macromolecular synthesis pathways, which may indicate that the antimicrobial activity of this 
compound is time or concentration dependent. 
 
Table 3.2 Effects of the four antibiofilm molecules and comparator agents at 4 x MIC on S. 
aureus SH1000 cellular membranes. Values are the means of at least three (Randall et al., 
2013a)biological replicates (+ SD). S. aureus SH1000 cells were treated with antibacterial 
agents for 10 minutes to determine membrane integrity, and 60 minutes to determine membrane 
potential. 
 3-0-1 Effects of ABMs on S. aureus cellular membranes 
Antibacterial agent 
% S. aureus membrane 
integrity (10 min) 
% S. aureus membrane 
potential (60 min) 
None 100 + 0 100 + 5 
4-45 2 + 1 0 + 4 
CIM008405 4 + 3 0 + 4 
Nisin 5 + 1 0 + 3 
P1a-PEP1 71 + 4 43 + 4 
P2-5 0 + 5 0 + 7 
Tetracycline 98 + 6 97 + 6 
 
Taken together, the MMS, BacLightTM and DiSC3(5) data suggest that all four ABMs exert their 
antimicrobial activity against S. aureus by disrupting the cell membrane. To further resolve the 
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MOA, the ability of the four ABMs to compromise the integrity carboxyfluorescein-filled 
staphylococcal liposomes was assessed. This assay was used to determine if membrane damage 
was a consequence of direct disruption of the phospholipid bilayer. Staphylococcal liposomes 
had a composition analogous to the phospholipid bilayer of the S. aureus cytoplasmic 
membrane (approximately 60% [wt/wt] phosphatidylglycerol, 40% cardiolipin) (Randall et al., 
2013a). S. aureus liposomes (50 µM) were challenged for 10, 60 and 180 min with 4 x MIC 
ABMs (Table 3.3). The leakage of carboxyfluorescein from the liposomes was monitored and 
percent liposome integrity was calculated relative to liposomes challenged with 0.5% Triton X-
100 (corresponding to 100% liposome damage [0% liposome integrity]). As carboxyflourescien 
leaks out of the liposomes, it goes from a quenched to non-quenched state, and is therefore 
directly proportional to fluorescence. All four ABMs and the known membrane disruptor, SDS, 
caused damage by targeting the phospholipid component of the membrane. After 10 minutes, a 
greater than 50 % loss of staphylococcal liposome integrity was observed, and ~ 90 % or greater 
after an hour (Table 3.3). Results may therefore indicate that the membrane interaction of 4-45, 
CIM008405, P2-5 and P1a-PEP1 is surfactant-like, directly disrupting the staphylococcal lipid 
bilayer. 
Antibacterial agents that exert their antibacterial effects through membrane perturbation have 
often been shown to lack prokaryotic specificity . Subsequently, the ability of the four ABMs to 
compromise the integrity of carboxyfluorescien-filled liposomes made of a phospholipid 
content matching that of mammalian cell membranes was assessed, to determine if their effect 
was specific to prokaryotic phospholipids. Mammalian liposomes were composed of 
approximately 50 % [wt/wt] phosphatidylcholine, 50% phosphatic acid, following the same 
procedure employed for staphylococcal liposomes. The four ABMs, which caused 
carboxyfluorescein leakage from staphylococcal liposomes exhibited comparable effects on 
mammalian liposomes. After 10 minutes a loss of greater than 40 % integrity was observed, and 
100 % integrity was lost after an hour (Table 3.3). Since the ABMs exhibited equivalent damage 
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to both mammalian and staphylococcal liposomes, it would suggest that these agents have a 
non-specific interaction with the membrane, targeting both prokaryotic and eukaryotic cells.  
 
Table 3.3 Effect of the four ABMs (4-45, CIM008405, P1a-PEP1, P2-5) and comparator agents 
on % S. aureus liposomeliposome and % mammalian liposome integrity after 10 minutes, 60 
minutes and 180 minutes challenge at 4 x MIC (+ SD). Values are the means of at least three 
biological replicates.  ABMs on S. aureus and mammalian liposome integrity 
 % Staphylococcal liposome integrity  
(+ SD) 
 % Mammalian liposome integrity  
(+ SD) 
Antibacterial 
agent 
10 
minutes 
60 
minutes 
180 
minutes 
10 
minutes 
60 
minutes 
180 
minutes 
4-45 47 + 9 0 + 9 0 + 10  31 + 10 0 + 10 0 + 6 
CIM008405 32 + 9 12 + 8 0 + 10 1 + 10 0 + 10 0 + 7 
P1a-PEP1 12 + 9 7 + 10 5 + 10 37 + 8 0 + 9 0 + 10 
P2-5 0 + 10 0 + 9 0 + 10 0 + 5 0 + 10 0 + 7 
SDS 41 + 10 0 + 10 0 + 9 0 + 8 0 + 8 0 + 7 
Tetracycline 100 + 4 100 + 5 99 + 9 100 + 3 100 + 6 100 + 9 
Vancomycin 98 + 7 98 + 10 97 + 9 99 + 5 99 + 7 99 + 5 
 
Since mammalian liposomes represent only the phospholipid component of the membrane, the 
four ABMs were also tested for their ability to cause haemolysis of mammalian erythrocytes 
(Table 3.4). Prokaryotic specific agents tetracycline and vancomycin caused <3% loss in 
erythrocyte integrity in one hour (Table 3.4). In comparison, agents that are known not to be 
prokaryotic specific, such as SDS, induced complete haemolysis of erythrocytes (Table 3.4). 
The four ABMs (4-45, CIM008405, P1a-PEP1, P2-5) that damaged both staphylococcal and 
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mammalian liposomes caused complete or near complete lysis of erythrocytes, further 
suggesting a lack of prokaryotic specificity (Table 3.4).  
 
Table 3.4 Effect of the four ABMs (4-45, CIM008405, P1a-PEP1, P2-5) and comparator agents 
on erythrocytes at 4 x MIC (+ SD). Values are the means of at least three biological replicates. 
Table 3-0-2 Effet of ABMs on erythrocytes 
Antibacterial agent 
% Erythrocyte integrity 
(+ SE) 
None 100 + 0 
4-45 0 + 3 
CIM008405 0 + 8 
Nisin 55 + 9 
P1a-PEP1 14 + 10 
P2-5 0 + 10 
SDS 0 + 1 
Tetracycline 99 + 1 
Vancomycin 97 + 8 
Results therefore indicate that the antibacterial target of the four ABMs (4-45, CIM008405, 
P1a-PEP1 and P2-5) is the staphylococcal membrane, specifically the phospholipid bilayer. 
However, this effect is not specific, causing comparable damage to eukaryotic cells.  
3.3.3 Analysis of surface immobilized antibiofilm molecules 
To determine if the five ABMs were still active upon covalent binding to smooth and open 
porous titanium disks, their in vitro activity profile was determined. Originally compound 4-45 
was selected as one of the five best ABMs. However, the toxicity profile of this compound was 
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less favorable, and was therefore replaced by the structural analogue LC0024, which exhibited 
similar antibiofilm activity as compared to 4-45, but reduced toxicity against OB, MSC and EC 
cells.  Therefore, this compound was used as a replacement of the originally selected 4-45 for in 
vitro and in vivo activity tests described below. Since each compound exhibited species-specific 
activity, compound-disk substrates were tested against the bacterial or fungal organism against 
which they were most active. Titanium disks were 0.5-1 cm wide, and were coated in either 
smooth or open porous surfaces. Open porous surfaces promote osseointegration on dental and 
orthopaedic implants, but are also at a higher risk of biofilm associated infections, as a 
consqeunce of increased bacterial attachment. Smooth surfaces were therefore also assessed.  
The five ABMs (CIM008405, LC0024, P1a-PEP1, P2-5, Tocris 2611) were immobilised onto 
either smooth or open porous titanium disks. Briefly, titanium surfaces were functionalized with 
an amino-group by treatment with Fmoc-protected 3-aminopropyl-triethoxy silane, followed by 
deprotection (Carpino, 1987). Functionalized disks were then placed in a hydrolysis vessel 
containing a solution (1 mL/disc) of n-heptane/hexamethylene diisocyanate (85:15) for 3 hours 
at room temperature. Samples were rinsed with n-heptane and placed in a vessel containing 
compounds dissolved in 100 mL dimethyl sulfoxide. After 16 hours, the disks were rinsed with 
demineralized, pyrogen-free water and subsequently with acetone, after which disks were 
allowed to dry (Figure 3.3b). This work was performed by the COATIM partner, Hemoteq 
(Aachen, Germany). 
 
3.3.3.1 In vitro activity of ABM-coated smooth disks 
With the exception of Tocris 2611, all other work described in this section was performed by 
other COATIM members.  
To promote biofilm formation, the ABM-coated smooth titanium disks were treated with foetal 
bovine serum overnight, before being exposed to inoculated media for 24 hours. Biofilm 
inhibition was calculated as a percentage of the negative control (disks containing no ABM 
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coating). Compounds P1a-PEP1 and P2-5 were found to be most active against fungal 
organisms, and therefore disks coated with these ABMs were tested against C. albicans. P1a-
PEP1 and P2-5 caused a reduction in C. albicans biofilm growth relative to the uncoated control 
of approximately 70 and 85 % respectively (Table 3.5). Compared to control antifungal agent 
(caspofungin) which reduced biofilm growth by greater than 99 % (Table 3.5). However, no 
P1a-PEP1 could be detected upon HMDI coating. As such, it is unclear if the observed 
antibiofilm activity is due to P1a-pep1 concentrations below the minimal detection limit or due 
to the coating procedure. No further studies were therefore performed with P1a-PEP1. ABMs 
LC0024 and Tocris 2611 reduced biofilm growth by approximately 25-35 % in S. aureus 
ATCC6538 and S. aureus SH1000 respectively. Antibacterial ABM CIM008405 (KU Leuven) 
exhibited no prevention in P. aeruginosa PA14 biofilm formation relative to the uncoated 
control (Table 3.5), whilst control antibacterial agent vancomycin reduced the formation of S. 
aureus ATCC6538 biofilms by 87 % (Table 3.5). 
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Table 3.5 Effects of smooth titanium surface immobolised ABMs (CIM008405, LC0024, P1a-
PEP1, P2-5, Tocris 2611) and comparator agents on biofilm formation. ND – not determined. 
Compound on smooth 
titanium disk 
Test strain 
Concentration 
(pmol/cm2) 
% Inhibition of 
biofilm growth after 
24 hours 
Caspofungin C. albicans SC5314 2191.4 > 99.5 
CIM008405 P. aeruginosa PA14 54.8 0 
LC0024 S. aureus ATCC6538 ND 25 
P1a-PEP1 C. albicans SC5314 0 69 
P2-5 C. albicans SC5314 315.2 > 85 
Tocris 2611 S. aureus SH1000 104.3 34 
Vancomycin S. aureus ATCC6538 0/35.2 87 
Table 3-0-3 Effects of smooth titanium surface-immobilised ABMs on biofilm form 
3.3.3.2 In vitro activity profile of ABM coated open porous disks 
With the exception of Tocris 2611, all other work described in this section was performed by 
other COATIM members.  
Experiments to determine the in vitro activity of the ABM coated open porous disks were 
equivalent to those used for the smooth disks, with the exception that inhibition of biofilm 
growth was determined for the ABM coated side of the disks only (as opposed to the whole 
disk, including both ABM coated and uncoated surfaces) and a lower inoculum was used for 
bacterial cultures. These changes were implemented due to the inoculum used for tests 
involving smooth titanium disks being significantly higher than that exhibited in vivo, and the 
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consideration that there might be an increase in activity observed if the non ABM-coated 
surfaces of disks are excluded. 
Immobilised onto an open porous titanium surface, antifungal ABM P2-5 (KU Leuven) was 
unable to prevent the formation of C. albicans SC5314 biofilms relative to the uncoated control 
(Table 3.6). Antifungal control agent caspofungin also exhibited poor biofilm prevention 
activity against C. albicans SC5314 biofilms, with only 6 % inhibition of biofilm growth 
relative to the uncoated control (Table 3.6). Similarly, ABM CIM008405 (KU Leuven) also 
displayed poor biofilm prevention activity, preventing the formation of P. aeruginosa PA14 
biofilms by 13 % (Table 3.6). Antibacterial ABM LC0024 and control agent vancomycin had 
comparable activity, preventing S. aureus ATCC6538 biofilm formation by 29 % (Table 3.6)  
(KU Leuven). The reduction in antibiofilm activity observed on open porous surfaces may be 
due to their being favourable for biofilm formation as a consequence of increased bacterial 
adherence to the irregularity of the surface. 
On open porous surfaces, ABM Tocris 2611 exhibited the most potent antibiofilm activity, 
preventing the formation of S. aureus SH1000 biofilms by 53 % relative to the uncoated control.  
Although Tocris 2611 exhibited improved biofilm prevention activity on the open porous 
surface, this could be due to the increased concentration of surface bound Tocris 2611 achieved, 
compared with that on the smooth titanium disks (approximately 10 x as much). 
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Table 3.6 Effects of five ABMs (CIM008405, LC0024, P1a-PEP1, P2-5, tocris 2611) and 
comparator agents on biofilm formation when immobolised to an open porous titanium surface. 
Table 3-0-4 Effects of porous titanium surface-immobilised ABMs on biofilm formation 
Compound on open 
porous  titanium disk 
Test strain 
Concentration 
(pmol/cm2) 
% Inhibition of 
biofilm growth after 
24 hours 
Caspofungin C. albicans SC5314 5468.26 6 
CIM008405 P. aeruginosa PA14 390.05 13 
LC0024 S. aureus ATCC6538 ND 29 
P2-5 C. albicans SC5314 2126.11 1 
Tocris 2611 S. aureus SH1000 1011.38 53 
Vancomycin S. aureus ATCC6538 169.87 29 
 
 
3.3.4 In vivo activity profile of ABM coated smooth and open porous disks 
All work described in this section was carried out by other COATIM members. 
As part of the development of the ABM coated surfaces for medical implants, the titanium 
substrates were tested using a subcutaneous in vivo biofilm model system in mice. Experiments 
were performed using smooth titanium disks only, due to several problems with the open porous 
surfaces, such as the animals exhibiting clear signs of pain and difficulties in removing the 
disks. The antibiofilm activity of the antibacterial ABMs (CIM008405, LC0024, Tocris 2611, 
vancomycin) was assessed against S. aureus SH1000, whilst C. albicans SC5314 was used to 
test antifungal ABM, caspofungin. P2-5 did not undergo in vivo assessment, due to poor in vitro 
activity. 24 hours after implantation of the ABM-coated disks, S. aureus or C. albicans were 
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injected subcutaneously at 1 x 107 and 1 x 108 cells respectively. Mice infected with S. aureus 
were then sacrificed 48 hours post injection, whilst mice infected with C. albicans were 
sacrificed 96 hours after infection. Following animal sacrifice, disks were removed and 
percentage biofilm inhibition relative to the uncoated control was determined.  
Against S. aureus SH1000 biofilms CIM008405, LC0024 and Tocris 2611 did not influence in 
vivo biofilm development. However, in comparison to the control (non-coated) disk, 
vancomycin-coated disks resulted in a statistically significant (p<0.05) reduction in biofilm 
formation. Titanium disks coated in antifungal control agent, caspofungin, also significantly 
prevented (p<0.05) in vivo biofilm development, of C. albicans, compared to the uncoated 
control.  
3.4 Conclusions 
The five best ABMs (4-45, CIM0008405, P1a-PEP1, P2-5 and Tocris 2611) were identified 
from a panel of 56, based on their spectrum of activity and toxicity profiles against C. elegans 
and the three most relevant bone tissue cell types; osteoblasts, bone marrow derived stem cells 
and endothelial cells. P1a-PEP1 and P2-5 were most active against fungal pathogens such as C. 
albicans, whilst 4-45, CIM008405 and Tocris 2611 target bacterial pathogens such as S. aureus 
and P. aeruginosa. The MOA of 4-45, CIM008405, P1a-PEP1 and P2-5 was determined in S. 
aureus SH1000 cultures. None of the four ABMs caused preferential inhibition of DNA, RNA 
or protein synthesis, but all caused loss of membrane integrity and membrane potential. These 
findings clearly indicate that all of the compounds exert their antibacterial effects through 
membrane perturbation. The ABMs also caused destruction of both staphylococcal and 
mammalian liposomes and complete or near complete lysis of equine erythrocytes, indicating a 
direct effect of these compounds on the phospholipid bilayer, and a lack of prokaryotic 
specificity. It can therefore be considered that the phospholipid bilayer of the cytoplasmic 
membrane in S. aureus is the cellular target. All agents tested exhibited more promising biofilm 
prevention activity when immobolised to smooth titanium surface, then when immobolised to 
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an open porous titanium surface. However, smooth and open porous disks were assessed 
following alternate methodology. With exception of control compounds vancomycin and 
caspofungin, none of the ABMs exhibited any effect on biofilm formation in vivo. However, 
this work provides a novel approach for the coating medical implants, to which other, more 
successful antibiofilm compounds could be applied.  
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Chapter 4 
Anti-staphylococcal activity and mechanism of action 
of Tocris 2611 
4.1 Abstract 
In search of novel antibiofilm molecules, research performed by the COATIM project identified 
compound Tocris 2611, which exhibited potent antibacterial activity against staphylococci, 
including staphylococcal biofilms. Consequently, Tocris 2611 may have potential for use in the 
healthcare setting as an anti-staphylococcal agent. As part of the development of novel 
antibacterial agents, pre-clinical assessment must involve elucidation of the mechanism of 
action. Investigations therefore attempted to identify the antibacterial target of Tocris 2611 
against the Gram-positive pathogen Staphylococcus aureus. Initial studies revealed that Tocris 
2611 causes simultaneous and non-preferential inhibition of DNA, RNA and protein 
biosynthesis, a signature often seen for compounds that damage the bacterial membrane. Further 
investigations demonstrated that Tocris 2611 caused a substantial loss of membrane integrity 
and complete loss of membrane potential, but not as a consequence of direct interaction with the 
phospholipid component of the cell membrane. Subsequently, Tocris 2611 was shown to exhibit 
potent bactericidal activity against staphylococci independent of their growth state, including 
cell types ordinarily present in biofilms. These results imply that Tocris 2611 exerts its 
antibacterial effects through perturbation of the bacterial membrane, enabling eradication of 
biofilms as a consequence of bacterial killing regardless of growth state. Additionally, low level 
resistance potential was observed for Tocris 2611, generated only by continuous selection. 
Results indicate that Tocris 2611 warrants further investigation as a candidate for the treatment 
of staphylococcal, biofilm-associated infections. 
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4.2 Introduction 
Biofilms provide protection for bacteria from the host immune system and are recalcitrant to 
antibiotics (particularly due to slow-or non-growing (SONG) bacteria, including persister cells 
present in biofilms) (Lebeaux et al., 2014, Lewis, 2001). Consequently, currently available 
antibiofilm therapies are largely ineffective, often making these types of infections untreatable. 
This is especially problematic in the clinical environment, particularly when associated with 
indwelling medical devices. Indeed, it is estimated that 15-25% of implant failures are due to 
infections involving a biofilm component.  
Therefore, as discussed in Chapter 3, the COATIM project assessed a number of novel 
antibiofilm molecules (ABMs) for their ability to prevent biofilm formation when adhered to a 
titanium surface. Surfaces were representative of those used for implanted medical devices, with 
the aim of addressing the current issues of implant failure due to infection attributed to biofilm 
formation. Based on their spectrum of activity and relative toxicity against eukaryotic cells, five 
ABMs (4-45, CIM008405, P1a-PEP1, P2-5, Tocris 2611) were selected for further evaluation. 
The phospholipid bilayer of the cytoplasmic membrane was identified as the cellular target for 
four (4-45, CIM008405, P1a-PEP1, P2-5) ABMs, resulting in membrane perturbation. With the 
exception of Tocris 2611, none of the ABMs were able to eradicate pre-formed biofilms in 
vitro. Furthermore, Tocris 2611 was the only ABM to exhibit potent anti-staphylococcal 
activity, which is a vital characteristic given that staphylococci are the primary cause of 
hospital-acquired and indwelling medical device infections, frequently involving biofilm 
formation (Otto, 2008, Weinstein, 2001).  
Tocris 2611 was originally identified due to its biological activity against HMC-1 and breast 
cancer cells, leading to cycle arrest and apoptosis, in addition to its effects on cardiomyocytes, 
reducing damage caused by myocardial ischemia/reperfusion (Onai et al., 2004, Tanaka et al., 
2005, Tanaka et al., 2006). Subsequently, the O’Neill laboratory in collaboration with the 
Collins group, identified Tocris 2611 as a potential inhibitor of bacterial RNA polymerase 
(RNAP), using in  silico docking  (Mariner, 2011). However, further experimentation revealed 
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that Tocris 2611 was not active against RNAP in vitro (Mariner, 2011), but nevertheless 
possessed potent anti-staphylococcal activity, and the rarely seen ability to eradicate pre-formed 
staphylococcal biofilms. A more extensive analysis was therefore required to elucidate the 
MOA of Tocris 2611 against both planktonic and biofilm communities of S. aureus SH1000. 
 
4.3 Aims and objectives 
Work described in this chapter aimed to characterise the mechanism of antibacterial activity of 
Tocris 2611 against planktonic and biofilm populations of S. aureus. Studies also intended to 
identify the potential for bacterial resistance to emerge against this novel compound. 
 
4.4 Results and Discussion 
4.4.1 Anti-staphylococcal activity of Tocris 2611 
The activity of Tocris 2611 was determined against four staphylococcal strains; S. aureus 
SH1000, USA300, UAMS-1 and S. epidermidis RP62A. Testing different strains of 
staphylococci is important as they have distinct properties, such as differences in the 
composition of the biofilm matrix (Jorgensen and Ferraro, 2009, Olson et al., 2002).  
Tocris 2611 exhibited activity against the four individual staphylococcal strains comparable to 
established antimicrobial agents, with an MIC of 0.125 µg/mL. Whilst, in contrast to the 
majority of current antimicrobial agents, Tocris 2611 also exhibited antibiofilm activity, which 
was assessed in two separate biofilm models; the Calgary Biofilm Device (CBD) and 96-well 
microtitre plate. The CBD enables high-throughput screening for preliminary evaluation of 
compounds, but supports the growth of only low cell density biofilms, which are likely 
immature. An alternative biofilm model was therefore used to assess the effects of Tocris 2611, 
where biofilms were grown in the wells of a 96-well plate, achieving a higher cell density. 
Tocris 2611 eradicated staphylococcal biofilms at 8 µg/mL and 64 µg/mL in the CBD and 96-
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well microtitre plate, respectively. Although a reduction in activity was observed against mature 
biofilms, Tocris 2611 still retained eradication properties. This effect was not seen for any other 
antimicrobials tested, which were unable to eradicate biofilms on either device at concentrations 
<256 µg/mL. Furthermore, compounds which exhibit activity against established biofilms are 
predominantly bactericidal, which may indicate that Tocris 2611 possesses bactericidal activity 
(Otto, 2014). 
 
4.4.2 Elucidation of the mode of action of Tocris 2611 against planktonic S. aureus 
4.4.2.1 Effects of Tocris 2611 on the major macromolecular synthesis pathways 
As discussed in Chapter 3, the antibacterial  effect  of a compound is often due to specific 
inhibition of one of the major biosynthetic pathways (e.g. DNA, RNA or protein) (O'Neill and 
Chopra, 2004). To establish whether Tocris 2611 inhibits one or more of these pathways, 
macromolecular synthesis was monitored by measuring incorporation of radiolabeled precursors 
into DNA, RNA, and protein. At 4 x MIC Tocris 2611 caused non-preferential inhibition of 
DNA, RNA, or protein synthesis within 10 minutes, a signature often seen for compounds that 
exert their antibacterial effect through perturbation of the bacterial membrane (Figure 4.1) 
(O'Neill and Chopra, 2004, Ooi et al., 2009). In comparison, ciprofloxacin, rifampicin and 
tetracycline, which are known to inhibit only DNA, RNA and protein synthesis, respectively, 
resulted in a specific response (Figure 4.1). 
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Figure 4.1 Effects of Tocris 2611 and control agents on the relative incorporation of 
radiolabelled (3H) thymidine, uridine and glutamine into DNA, RNA and protein, respectively. 
Error bars show standard deviation from the means of at least three independent experiments. 
Figure 4. 1 
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4.4.2.2 Assays to determine if Tocris 2611 targets the staphylococcal membrane 
To explore further whether the MOA of Tocris 2611 is through disruption of the cytoplasmic 
membrane, the BacLightTM and DiSC3(5)  assays were used to measure membrane integrity and 
measure membrane potential, respectively. In a 10 minute BacLightTM assay, S. aureus cells 
exposed to nisin (a known membrane damaging compound which forms pores in the membrane 
(Ruhr and Sahl, 1985)) and Tocris 2611, resulted in a membrane integrity of 5% and 45%, 
respectively (Table 4.1). Tocris 2611 also caused a 100% decrease in membrane potential in 1 
hour (Table 4.1). This result is comparable to the surfactant sodium dodecyl sulfate (SDS) 
which caused 100% loss of membrane potential (Table 4.1). SDS causes membrane perturbation 
and depolarisation by forming micelles that target the membrane lipids. Results may therefore 
suggest that the antibacterial MOA of Tocris 2611 is through disruption of the bacterial 
membrane and subsequent leakage of intracellular components. 
Compounds that target the bacterial membrane frequently demonstrate the same effect against 
mammalian cells, which is an undesirable characteristic for an antimicrobial drug candidate.  
Tocris 2611 was therefore tested for its ability to cause haemolysis of mammalian erythrocytes 
at 4 x MIC (Table 4.2). As expected, the prokaryote specific agents tetracycline and 
vancomycin caused <3% loss in erythrocyte integrity in 1 hour. In comparison, agents which are 
known to not be prokaryote specific and also cause membrane damage, such as SDS, induced 
complete haemolysis of erythrocytes. Tocris 2611 resulted in a decrease in erythrocyte integrity 
of approximately 40%, an effect also demonstrated by the membrane damaging compound nisin 
(Table 4.2). 
 
 
 
 
57 
 
 
 
 
Table 4.1 Effect of Tocris 2611 and comparator agents at 4 x MIC on S. aureus SH1000 
cellular membranes, and erythrocyte integrity.  Values are the means of at least three biological 
replicates (+ SD). ND indicated not determined. NDC indicated no drug control. 
Antibacterial agent 
% S. aureus 
membrane intregity 
(+ SD) (10 min) 
% S. aureus 
membrane potential 
(+ SD) (60 min) 
% Erythrocyte 
integrity (+ SD) 
(60 min) 
NDC 100 + 0 100 + 5 100 + 0 
Nisin 5 + 1 0 + 3 55 + 9 
SDS 0 + 0 0 + 2 0 + 1 
Tetracycline 98 + 6 97 + 6 99 + 1 
Tocris 2611 45 + 2 0 + 7 62 + 7 
Vancomycin 100 + 4 ND 97 + 8 
 
 
As demonstrated in Chapter 3, the antibacterial effects of membrane damaging compounds can 
be a consequence of direct interaction with the phospholipid bi-layer; therefore the ability of 
Tocris 2611 to compromise the integrity the phospholipid bi-layer was assessed. 
Carboxyfluorescein-filled liposomes with a composition analogous to the phospholipid bi-layer 
of the S. aureus CM (approximately 60% [wt/wt] phosphatidylglycerol, 40% cardiolipin) were 
challenged with 4 x MIC Tocris 2611. Damage was measured at 10, 60 and 180 minutes (Table 
4.2). After 180 minutes S. aureus liposomes only exhibited a loss of 9% integrity. In contrast, 
SDS caused a substantial (59%) loss in integrity after only 10 minutes, and completely degraded 
liposomes (100% loss in integrity) after 60 minutes (Table 4.2). These results strongly suggest 
that the MOA of Tocris 2611 does not involve targeting the phospholipid component of the cell 
membrane. In order to investigate whether the previously observed haemolytic effect of Tocris 
2611 results from direct interaction of the drug with the mammalian phospholipid bilayer, 
mammalian liposomes were synthesised and challenged with the Tocris 2611.Mammalian 
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liposomes (50 % [wt/wt] phosphatidylcholine, 50% phosphatidic acid) were therefore 
challenged with 4 x MIC Tocris 2611. No appreciable activity was observed, with a loss of 
integrity of 3 % after 180 minutes (Table 4.2). 
Failure to observe activity against staphylococcal liposomes implies that Tocris 2611 likely 
exerts its antibacterial effect through interaction with one or more membrane proteins. 
Therefore, to provide further insight into the membrane component targeted by Tocris 2611, 
attempts were made to generate staphylococcal proteoliposomes. However, despite some 
experimental progress, studies could not be included in this work due to time constraints.  
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Table 4.2 Effect of Tocris 2611 and comparator agents on % S. aureus liposome integrity after 10 minutes, 60 minutes, 180 minutes challenge at 4 x MIC 
(+SD). Values are means of at least three biological replicates. NDC indicates no drug control. 
 
Table 4-0-1 Effect of Tocris2611 and comparator agents on S. aureus liposome integrity
 % Staphylococcal integrity (+SD) % Mammalian liposome integrity (+SD) 
Antibacterial 
Agent 
10 minutes 60 minutes 180 minutes 10 minutes 60 minutes 180 minutes 
NDC 100 + 0 100 + 0 100 + 0 100 + 0 100 + 0 100 + 0 
SDS 41 + 10 0 + 10 0 + 9 0 + 8 0 + 8 0 + 7 
Tetracycline 100 + 4 100 + 5 99 + 9 100 + 3 100 + 6 100 + 9 
Tocris 2611 97 + 6 92 + 7 91 + 9 99 + 5 99 + 6 97 + 6 
Vancomycin 98 + 7 98 + 10 97 + 9 99 + 5 99 + 7 99 + 5 
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4.4.3 Antibiofilm activity of Tocris 2611 
Tocris 2611 demonstrated potent anti-staphylococcal activity against both planktonic and 
biofilm cultures, and the MOA against planktonic cultures was determined to be through 
membrane perturbation. Investigations therefore sought to evaluate the mechanism by which 
Tocris 2611 eradicates biofilms. 
4.4.3.1 Activity of Tocris 2611 against slow or non-growing staphylococcal cells 
Compound-mediated eradication of biofilms may occur through two possible mechanisms; 
disruption of the biofilm matrix or comprehensive killing (sterilisation) of bacteria within the 
biofilm. Since biofilm communities are highly recalcitrant to antimicrobial therapy due to slow 
or non-growing (SONG) cells, the ability of Tocris 2611 to kill both these cell types was 
assessed. Initially, the effect of Tocris 2611 and comparator agents on the viability of 
exponential and stationary phase cells was determined over a period of 24 hours (Figure 4.2).  
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Figure 4.2 Killing kinetics of Tocris 2611 at 4 x MIC (0.5 µg/mL), 8 µg/mL (Calgary MBEC) 
and 64 µg/mL (well MBEC) and comparator agents (daptomycin, tetracycline and XF-73) at 4 x 
MIC, against exponential phase and early stationary phase cultures of S. aureus SH1000 over 24 
hours. Panel (a): exponential phase cultures; Panel (b) stationary phase cultures. Values are the 
means of at least three biological replicates; error bars show standard deviations. 
 
Figure 4. 2 
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At 4 x MIC, Tocris 2611 was bacteriostatic against exponentially growing cells, demonstrating 
a <1 log drop in cell viability over 24 hours, a result comparable to tetracycline (Figure 4.2a). 
At 8 µg/ml (CBD MBEC), Tocris 2611 became bactericidal against exponentially growing 
cells, with a log drop in cell viability of >3 over 24 hours, which is comparable to daptomycin 
(Figure 4.2a).  No significant bactericidal activity was observed against stationary phase cells at 
these concentrations (Figure 4.2b). In contrast, Tocris 2611 at 64 µg/mL (well MBEC) was 
highly effective at killing both stationary phase and exponentially growing cells, achieving 
sterilisation after 6 hours (limit of detection 10 cfu/mL), and 3 hours respectively (Figure 4.2a 
and Figure 4.2b). Whereas, daptomycin was essentially inactive against stationary phase 
cultures (Figure 4.2b). 
Subsequent investigations assessed the activity of Tocris 2611 against populations of persister 
cells. At 64 µg/mL (well MBEC), exposure to Tocris 2611 resulted in a complete loss of cell 
viability after 24 hours, an effect not seen by any of the other agents tested, with the exception 
of XF-73, a potent anti-staphylococcal agent which exerts its antibacterial effect through 
membrane disruption, and possesses bactericidal activity (Figure 4.3).  
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Figure 4.3 Effect of Tocris 2611 and comparator agents on the survival S. aureus SH1000 
persister cell cultures isolated by selection with exposure to 10 x MIC ciprofloxacin or 10 x 
MIC ampicillin. Tocris 2611 was added at 4 x MIC (0.5 µg/mL), 8 µg/mL (Calgary MBEC) and 
64 µg/mL (well MBEC), whilst comparator agents were added at 4 x MIC. Values are the 
means of at least three biological replicates. 
Figure 4. 3 
4.4.3.2 Effect of Tocris 2611 on biofilm structure 
Since it has been demonstrated that Tocris 2611 retains antibacterial activity against SONG 
cells found in biofilm communities, the antibiofilm activity of Tocris 2611 is most likely 
through the sterilisation of viable cells within the biofilm. Furthermore, visual assessment of the 
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biofilm after treatment with biofilm eradicating concentrations of Tocris 2611, followed by 
staining with 5% crystal violet, suggested that the matrix/superstructure of the biofilm was 
largely unaffected. This finding was corroborated by quantifying the proportion of matrix and 
cells after 24 hours exposure to Tocris 2611 and comparator agents (Figure 4.4). Quantitative 
analysis used the matrix-specific stain SYPRO Ruby, and bacterial cell stain SYTO 9. After 24 
hours exposure to biofilm eradicating concentrations of Tocris 2611, the reduction in cell 
viability was far greater than the effects observed on the matrix, with a log drop in cell viability 
of twice as much as that in matrix (Figure 4.4). However, there was still a notable loss of matrix 
material in comparison to untreated biofilms.  To determine whether dispersion of the biofilm, 
resulting in a reduction of matrix material, is an indirect effect of bacterial killing by Tocris 
2611, quantification of matrix and cells was repeated following six hours exposure to Tocris 
2611 (Figure 4.4). Tocris 2611 achieves sterilisation of stationary phase cultures within six 
hours, therefore providing a more representative effect on the biofilm structure. After six hours, 
Tocris 2611 caused essentially no loss of adherent material, whilst leading to a substantial loss 
of bacterial viability, comparable to that observed after 24 hours (Figure 4.4). This suggests that 
destructuring of the biofilm is a consequence of cell death, and the antibiofilm activity of Tocris 
2611 does not involve biofilm disruption (Figure 4.4). 
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Figure 4.4 Effects of Tocris 2611 and comparator agents on the proportion of matrix and cells 
of S. aureus SH1000 biofilms. Panel (a): after 24 hours exposure to proteinase K (100 µg/ml.) 
and Tocris 2611 64 µg/ml (96-well MBEC); Panel (b) after 24 hours exposure to proteinase K 
(100 µg/ml), Tocris 2611 4 x MIC, 8 µg/ml and 64 µg/ml (Calgary Biofilm Device and 96-well 
MBEC respectively); Panel (c) after 6 hours exposure to proteinase K (100 µg/ml.) and Tocris 
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2611 64 µg/ml (96-well MBEC). Values are the means of at least three biological replicates; 
error bars show standard deviations. 
 
Taken together, results suggest that Tocris 2611 eradicates both planktonic and biofilm cultures 
of S. aureus by killing viable cells (including SONGs) through perturbation of the bacterial 
membrane. Indeed, there is a growing recognition of membrane damaging agents due their 
frequently seen ability to eradicate biofilms. The bacterial membrane is a fundamental requisite 
of both growing and SONG cells, and therefore serves as an ideal antibacterial target (assuming 
specificity for the bacterial membrane can be achieved). Since disruption of the membrane is 
not dependent on active biosynthetic pathways, membrane damaging agents are therefore often 
more effective than non-membrane damagers in the treatment of biofilm associated infections. 
However, not all agents known to target the bacterial membrane are able to eradicate biofilms, 
for example daptomycin has only limited antibiofilm activity against some types staphylococcal 
biofilm infections. Loss of effective antibiofilm activity may be attributed to the existence of 
different subpopulations within the biofilm, and varying compositions of the membrane 
between subpopulation, interfering with the interaction between the compound and the 
membrane. Therefore, although membrane damaging agents may provide a more effective 
alternative in the treatment of biofilm infections, targeting the bacterial membrane does not 
necessarily indicate that a compounds will possess antibiofilm activity.  
 
4.4.4 Investigating the propensity of S. aureus to develop resistance to Tocris 2611  
For clinical use an advantageous property for antimicrobials is a low potential for bacteria to 
develop resistance to the agent of interest. To determine if resistance readily develops as a 
consequence of exposure to Tocris 2611, both spontaneous resistance and resistance as 
consequence of prolonged exposure was assessed.  
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4.4.4.1 Selection of bacterial Tocris 2611 resistance 
Spontaneous resistance to Tocris 2611 of S. aureus SH1000 was evaluated by plating saturated 
cultures onto MHA containing 4 x MIC Tocris 2611.  No resistant mutants were isolated (limit 
of detection <5.0 X 10-9), indicating that bacterial resistance to Tocris 2611 requires multiple 
mutational steps. As such Tocris 2611 may be considered to exhibit a low resistance potential.  
Instead, resistance following prolonged selection with Tocris 2611 was investigated to 
determine whether a reduction in susceptibility would arise under continuous exposure to Tocris 
2611. This was done by continuously exposing five individual lineages of SH1000 to an 
extended concentration range of Tocris 2611 over 25 days (extended gradient MIC method, 
section 2.6.7). Resistance to Tocris 2611 arose in all five lineages, and mutants were 14 x less 
susceptible after 25 days (Figure 4.4). In contrast, three days of selection was sufficient to select 
clinically relevant levels of daptomycin resistance (≥2 µg/mL) (Figure 4.4). Although S. aureus 
mutants resistant to Tocris 2611 were selected over 25 days of continuous exposure, the level of 
resistance that was generated was still less than 1 µg/mL. Compared with daptomycin, the 
control antibiotic used in this study, for which up to 36 µg/mL resistance was selected in S. 
aureus. Daptomycin is currently used clinically to treat many multi-drug resistant strains of S. 
aureus, particularly for complicated skin and soft tissue infections. Furthermore, the MIC of 1 
µg/mL exhibited by the Tocris 2611 resistant strains is 8 and 64-fold lower than the biofilm 
eradicating concentrations of Tocris 2611 against biofilms grown the Calgary Biofilm Device, 
and 96-well plate respectively. Taken together, results may indicate that although bacterial 
resistance can emerge for Tocris 2611, it is low level and requires prolonged selective pressure. 
Therefore, it is reasonable to suggest that Tocris 2611 resistance would be unlikely to effect the 
development of this compound for use as an antibiofilm treatment.  
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Figure 4. 5 Resistance selection of S. aureus SH1000 to Tocris 2611 and control agent 
daptomycin. Panel (a): daptomycin; Panel (b); Tocris 2611. 
 
4.4.4.2 Characterisation of Tocris 2611 resistant strains 
To establish which genes impact the susceptibility of S. aureus to Tocris 2611, the most 
resistant strain (T2), generated by prolonged exposure to Tocris 2611, was analysed using 
whole-genome sequencing (WGS). WGS enables the identification of the genetic changes 
responsible for resistance. Seven mutations were confirmed, which are potentially involved in 
Tocris 2611 resistance (Table 4.5). Tocris resistant strain T2 exhibited an MIC of 1 µg/mL. 
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Table 4.3 Mutations in the DNA sequence of Tocris 2611 resistant strain T2 compared with 
wild-type S. aureus SH1000. Whole genome sequencing was used to identify genomic changes.  
Locus Function 
Nucleotide 
change 
Amino acid 
change 
Intergenic region upstream 
of SAOUHSC_00198 
Putative long-chain acyl-
CoA synthetase 
G39A - 
SAOUHSC_00467 pur operon repressor G88T V30L 
SAOUHSC_01070 Regulatory protein YlbF T78A Y26X 
SAOUHSC_01359 
Membrane modifying 
protein MprF 
C1711T L571F 
SAOUHSC_01621 
Transcription 
antitermination protein 
NusB 
C365T G122D 
SAOUHSC_02485 
DNA-directed RNA 
polymerase, alpha subunit 
G19T P7T 
Intergenic region upstream 
of SAOUHSC_02659 
Putative transcriptional 
regulator AcrR 
G43C - 
Deleted T46 - 
G47C - 
G50A - 
T51C - 
C52A - 
 
To determine if these mutations were universal for causing Tocris 2611 resistance, the genes 
and intergenic regions containing the mutations outlined in Table 4.5 were sequenced in the four 
other resistant strains generated. The same regions were also sequenced in the resistant strain 
T2, but at the five and ten day stage of Tocris 2611 exposure, to determine if an increase in the 
level of resistance observed could be attributed to a particular mutation. In addition to resistant 
strain T2, the alteration in DNA sequence of SAOUHSC_00467 (pur operon repressor) was 
identified in the 10 day T2 strain, and resistant strain T5. The mutation identified in membrane 
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modifying protein MprF (SAOUHSC_01359) was also identified in ten day T2, and the point 
mutation at 219191 was identified in both the five and ten day T2. Since reduced susceptibility 
to Tocris 2611 cannot be directly attributed to a specific mutation, it would suggest that the 
MOA of Tocris 2611 involves disruption of multiple targets, an effect which has been 
previously reported for membrane-active compounds. 
Mutations in mprF have also been identified in daptomycin, nisin and vancomycin resistant 
strains of S. aureus. Multiple peptide resistance factor (MprF) is a membrane protein, which 
adds L-lysine to phosphatidylglycerol (a phosphatidylglycerol lysyltransferase). The addition of 
L-lysine increases net positive charge of the bacterial cell surface, which is known to decrease 
the binding of daptomycin, and may have a similar effect on Tocris 2611. Mutations in DNA-
directed RNA polymerase have also been identified in daptomycin and vancomycin resistant 
strains of S. aureus. However DNA-directed RNA polymerase mutations in response to 
daptomycin and vancomycin exposure occur in the β-subunit or C-subunit, whereas mutation in 
the Tocris 2611 resistant strain was present in the α-subunit. It has been suggested that these 
mutations result in altered fluidity, surface charge and permeability of the cell membrane, and 
may therefore indicate that similar membrane alterations are involved in conferring reduced 
susceptibility to Tocris 2611. Furthermore, a mutation in long chain acyl-CoA synthestase, 
which is required for fatty acid biosynthesis, may also affect the membrane structure, causing 
reduced susceptibility to Tocris 2611. Three of the mutations (nusB, ylbF, and the region 
upstream of acrR) can be grouped into those that may impact the regulatory processes within 
the cell. Finally, mutations in the pur operon repressor are a frequently encountered artefact of 
selecting resistance in S. aureus. It has been suggested that the mutation allows for better 
growth in culture media.  
Results indicate that reduced susceptibility to Tocris 2611 occurs as consequence of the 
acquisition of multiple mutations, as opposed to one single point mutation. However, further 
work would be required to determine the cause of the reduced susceptibility of S. aureus to 
Tocris 2611(see Chapter 6).  
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4.5 Conclusions 
Tocris 2611 is a potent anti-staphylococcal agent which is able to eradicate S. aureus planktonic 
cells and biofilms (including community acquired MRSA USA300, and prolific biofilm former 
UAMS-1 and indeed S. epidermidis RP62A). In SH1000, it has been elucidated that its 
mechanism of action is through disrupting the cytoplasmic membrane. Although Tocris 2611 
also has some effect on eukaryotic cells, it only resulted in modest lysis of erythrocytes, 
demonstrating a degree of selective toxicity. Tocris 2611 also demonstrated a low resistance 
potential. Therefore, Tocris 2611 makes an interesting candidate as an anti-staphylococcal, 
antibiofilm agent.  
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Chapter 5 
Screening chemical libraries for potentiators of 
established antimicrobial agents 
5.1 Abstract 
Due to antibiotic resistance seen in both biofilm and non-biofilm bacterial infections, there is a 
pressing need for new antibacterial agents. However, it could take over 10 to 20 years before 
new antibiotics are accessible. One potential strategy to address this problem is repurposing 
existing drugs as antibiotic adjuvants, potentiating the activity of available antibiotics against 
resistant bacteria. Work described in this chapter screened 3 chemical libraries to identify 
adjuvants of the antibiotics ciprofloxacin and rifampicin against S. aureus SH1000 biofilms and 
rifampicin, fusidic acid or linezolid against planktonic E. coli 1411. No compounds were found 
to enhance the efficacy of ciprofloxacin or rifampicin against SH1000 biofilms, but many were 
shown to have a synergistic interaction with rifampicin and/or linezolid against E. coli 1411. A 
number of compounds also exhibited antibacterial activity alone. Further evaluation showed that 
the compounds and compound-antibiotic combinations, identified from this screen, had limited 
antibacterial activity against the clinically relevant ESKAPE pathogens. Although no antibiotic 
adjuvants were determined that could be considered for clinical use, drug repurposing and 
adjuvant therapy remain important approaches to antimicrobial drug discovery and 
development. In addition, these strategies may provide a temporary solution to the antibiotic 
resistance crisis, whilst adequate numbers of new antibiotics are made available.   
 
5.2 Introduction 
Bacterial resistance to available antibiotics is rapidly increasing, and poses a serious threat to 
human health. With the exception of the recently described Gram-positive antibacterial 
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teixobactin, that is considered to belong to a new class of antibiotic, no new classes have been 
discovered since 1987, and none have been introduced against Gram-negative bacteria for more 
than 40 years. Furthermore, the available treatments for biofilm-associated infections are limited 
and largely ineffective.  As a consequence, the need for novel antibiotics and alternative 
therapeutic options for both biofilm and non-biofilm infections has now become critical.  
However, the discovery, and subsequent development required for new compounds to reach 
FDA-approval can take up to, or even more than, 20 years.  
One alternative approach to this antibiotic pipeline is to repurpose existing drugs as antibiotic 
adjuvants, thereby enhancing the antibacterial activity of clinically available antibiotics. 
Adjuvants such as these are preferably non-antibiotic compounds (have no reported antibacterial 
activity), which are either FDA-approved for an alternative indication, or have under gone some 
pre-clinical evaluation. Two antibiotics can also be adjuvants if they interact synergistically.  
There are several properties that potential antibiotic adjuvants could possess. First, adjuvants 
could have direct antibacterial activity, which may or may not be used clinically. Second, 
adjuvants could overcome antibiotic resistance mechanisms. Adjuvants that are used to suppress 
bacterial resistance include, but are not limited to, efflux pump inhibitors, outer membrane 
permeabilisers and enzyme inhibitors, such as inhibitors against β-lactamase. In clinical use, 
agents such as flavones have been used successfully in combination with fluoroquinolone 
ciprofloxacin, by preventing efflux by NorA. Outer membrane permeabilisers have also been 
previously researched for use as antibiotic adjuvants, although none have been introduced into 
the clinic. Problems such as a lack of prokaryotic specificity render these compounds unsuitable 
for use in humans. Agents such as clavulanic acid, sulbactam and tazobactam, which are β-
lactamase inhibitors, have been co-administered with the penicillins for three decades. However, 
these examples are directed at non-biofilm infections, whilst approximately 80% of infections 
grow as a biofilm. It has recently been demonstrated that peptide 1018, a new class of adjuvant, 
synergizes with antibiotics ceftazidime, tobramycin, imipenem and ciprofloxacin, aswell as 
exhibiting broad-sprectum antibiofilm activity.  
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Finally, adjuvants could help clear infections by activating the host immune/defence 
mechanisms, such as promoting autophagy. Although any one of these properties would make a 
compound potentially useful as an antibiotic adjuvant, those that possessed more than one may 
be of greater value. Furthermore, the ability to achieve plasma concentrations that are 
comparable to the minimum inhibitory concentration required for antibacterial activity is also 
important. In addition, antibiotic/adjuvant combinations that have different molecular targets are 
often found to be more effective.  
Employing antibiotic adjuvants may therefore enable the use of antibiotics against bacteria 
which had either developed resistance, or to which were previously insensitive. Furthermore, 
they may decrease the rate of resistance developing. In addition, using repurposed drugs can 
reduce the cost of bringing a drug to market by up to 40 %, as well as the time spent in drug 
development being significantly reduced. Finally, chemicals libraries provide an ideal platform 
form for drug discovery, providing an extensive and diverse number of biologically relevant 
compounds. 
In view of this, three compound libraries of biologically active small molecules were evaluated 
for antibiotic adjuvants; the NIH Clinical Collection, Tocriscreen Total collection and the 
Spectrum Collection.  
The NIH clinical collection (727 compounds) consists almost entirely of drugs that have been 
used in phase I-III clinical trials and have not been represented in other arrayed collections. 
These compounds also have favourable attributes for inclusion in a screening collection, such as 
purity, solubility and commercial availability for re-supply (Cao et al., 2015). The collection 
was assembled by the NIH through the Molecular Libraries Roadmap Initiative as part of its 
mission to enable the use of compound screens in biomedical research (Austin et al., 2004). The 
clinically tested compounds in the NCC are highly drug-like with known safety profiles (Cao et 
al., 2015). This collection provides an excellent source of compounds which may be appropriate 
for direct human use in new disease areas.  
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Tocriscreen Total is a library of 1120 biologically active, well-characterised small molecule 
inhibiters (Dittmar et al., 2015). The collection covers a wide range of pharmacological targets 
(>300) and research areas, such as cancer and immunology and including a range of therapeutic 
classes, such as cardiovascular and nervous systems (Dittmar et al., 2015).  
The Spectrum Collection presents 2320 compounds of bioactive compounds and natural 
products, and includes all of the compounds in the US and International Drug Collections, 
together with our Natural Product and Discover libraries (Rochester et al, 2017). Compounds 
were selected by medicinal chemists and biologists to provide a wide range of biological 
activities and structural diversity for screening programs (Rochester et al, 2017). Sixty per cent 
of the library is made up of drugs that have been introduced in the US (~1280) and ~320 that are 
limited to use in Europe. A further 25% of the collection consists of natural products (~640) 
with unknown biological properties, derived from sources worldwide. (Rochester et al., 2017) 
These compounds were selected on the basis of chemical class and structural diversity. The final 
15% of the collection are non-drug enzyme inhibitors, receptor blockers, membrane active 
compounds and cellular toxins (Rochester et al., 2017). Many of these 420 compounds have 
either not reached development, or were dropped for toxicological or other reasons. Also 
included are representatives of marketed pesticides and herbicides for comparative purposes 
(Rochester et al., 2017).  
 Each library was individually screened in combination with clinically available antibiotics 
ciprofloxacin or rifampicin against S. aureus SH1000 biofilms, or rifampicin, linezolid or 
fusidic acid against planktonic cultures of E. coli 1411. Both ciprofloxacin and rifampicin were 
selected since they possess bactericidal activity, a property that is necessary for the successful 
eradication of biofilms (Wu et al., 2015). Indeed, previous reports suggest rifampicin does 
exhibit some activity against staphylococcal biofilms, although this is limited (Sanchez et al., 
2015). Furthermore, both compounds have alternate mechanisms of action, enabling a wider 
range of interactions to be assessed during screening. Rifampicin was also screened for 
potentiators against planktonic E. coli since this compound possesses potent broad-spectrum 
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antibacterial activity. However, due to a high resistance potential, rifampicin is only used in 
combination therapy, customarily for the treatment of tuberculosis (Campbell et al., 2001). 
Rifampicin resistance is most frequently due to a mutation in the β subunit of the RNA 
polymerase, which changes the structure (Campbell et al., 2001, Wehrli, 1983). Finally, fusidic 
acid and linezolid were screened potentiators against planktonic E. coli. Both fusidic acid and 
linezolid are narrow-spectrum antibiotics, possessing activity against Gram-positive organisms 
only (Dobie and Gray, 2003, Sztanke et al., 2004). They are also bacteriostatic, and kill bacteria 
through the inhibition of protein synthesis (Cundliffe, 1972, Sztanke et al., 2004). However, 
they interfere with bacterial protein synthesis in alternate mechanisms. Fusidic acid binds to 
bacterial protein elongation factor G (EF-G), trapping it to ribosome and preventing further 
elongation of the peptide (Dobie and Gray, 2003, McLaws et al., 2011). Linezolid inhibits 
protein synthesis by binding to the 50S subunit of the ribosome, preventing it from complexing 
with the 30S subunit, and other factors necessary to form the initiation complex (Livermore, 
2003, Sztanke et al., 2004). Following the initial screen with the NIH clinical collection, fusidic 
acid was substituted with linezolid, as it cannot be assumed that efflux is always the principal 
mechanism leading to the lack of Gram-negative activity. Whereas efflux is considered the 
primary cause of Gram-negatives reduced susceptibility to linezolid.  
 
5.3 Aims and Objectives 
Work described in this chapter aims to screen three chemical compound libraries (NIH Clinical 
Collection, Tocriscreen Total and Spectrum Collection) for antibiotic adjuvants, which 
potentiate the activity of ciprofloxacin or rifampicin against S. aureus SH1000 biofilms and 
rifampicin, linezolid or fusidic acid against planktonic E. coli 1411.  
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5.4 Results and Discussion 
5.4.1 Antibacterial properties of antibiotics screened in combination with chemical 
libraries 
To determine the appropriate concentrations at which the four antibiotics (ciprofloxacin, 
rifampicin, linezolid and fusidic acid) should be screened at, MICs and/or 96-well plate MBECs 
against standard laboratory strains S. aureus SH1000 or E. coli 1411 were determined. The four 
antibiotics (ciprofloxacin, fusidic acid, linezolid and rifampicin) exhibited MICs ranging from 
0.008-2 µg/mL against planktonic cultures of S. aureus, and 4 - >256 µg/mL against planktonic 
cultures of E. coli. None of the compounds were able to eradicate S. aureus biofilms grown in 
96-well plates (Table 5.1). Consequently, as no activity against staphylococcal biofilms was 
observed with ciprofloxacin and rifampicin, they were screened against SH1000 well grown 
biofilms at 50 µg/mL in combination with the three compound libraries. Similarly, fusidic acid 
and linezolid displayed no activity against planktonic E. coli 1411, and were therefore also 
screened at 50 µg/mL. Rifampicin exhibited an MIC of 4 µg/mL against planktonic E. coli 1411 
and was subsequently screened in combination with the three libraries at the sub-MIC 
concentration of 0.5 µg/mL. The three compound libraries were tested at 10 µM.  
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Table 5.1 Minimum inhibitory concentrations (MICs) and 96-well plate minimum biofilm 
eradication concentrations (well MBEC) of antibacterial agents ciprofloxacin, fusidic acid, 
linezolid and rifampicin, against planktonic and biofilm S. aureus SH1000 and planktonic E. 
coli 1411. ND indicates not determined.Table 5-0-1 MICs an against S. aureus and E. coli 
                                             Antibacterial Activity (µg/mL) 
Antibacterial 
Agent 
S. aureus SH1000  
planktonic MIC 
S. aureus SH1000 
well MBEC 
E. coli 1411  
planktonic MIC 
Ciprofloxacin 2 >256 ND 
Fusidic Acid 0.25 >256 >256 
Linezolid 2 >256 >256 
Rifampicin 0.008 >256 4 
 
5.4.2 Screen for S. aureus biofilm eradication 
The three compound libraries were screened in combination with ciprofloxacin and rifampicin 
against S. aureus SH1000 biofilms, to identify compounds that potentiated their activity against 
staphylococcal biofilms. S. aureus SH1000 has been used extensively in previous studies and 
forms a biofilm (Ooi et al., 2009, Ooi et al., 2010, Randall et al., 2013b).  
This screen identified no potentiators of ciprofloxacin or rifampicin which resulted in S. aureus 
biofilm eradication. The absence of any anti-staphylococcal antibiofilm activity observed could, 
in part, be attributed to the highly refractory nature of biofilms to most antimicrobials. 
Conceivably, higher concentrations of agents might have yielded more positive results.   
 
5.4.3 Screen for antibiotic adjuvants against E. coli  
The compound libraries in were screened for agents able to potentiate the activity of rifampicin, 
fusidic acid or linezolid against E. coli 1411 grown in planktonic culture.  
5.4.3.1 NIH clinical collection in combination with rifampicin or fusidic acid 
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No potentiators of rifampicin or fusidic acid activity against E. coli 1411 were discovered from 
the screen of the NIH clinical collection. However, the screen did identify 26 compounds which 
were active against planktonic E. coli 1411 at 10 µM. 25 of these were found to be pre-existing 
antibacterials and therefore underwent no further analysis. These were azithromycin, cefaclor, 
cefinir, cefixime trihydrate, cefotaxime sodium salt, cefuroxime, demeclocycline, enrofloxacin, 
floxuridine, gatofloxacin, levofloxacin, micocycline hydrochloride, moxifloxacin hydrochloride, 
norfloxacin, ofloxacin, ormetoprim, oxytetracycline hydrochloride, pazufloxacin, pefloxacin, 
pefloxacin mesylate, piperacillin sodium salt, rifabutin, rifampicin, terazosin, tosofloxacin 
tosylate,  and triclosan.  
Flecainide acetate was the sole compound discovered that exhibited unanticipated antibacterial 
activity. This drug is a class 1c antiarrhythmic agent used in the prevention and treatment of 
tachyarrhythmias, and works by blocking the Nav1.5 sodium channel in the heart, slowing the 
upstroke of the cardiac action potential and conduction of the electrical impulse within the heart. 
It has also been shown to inhibit ryanodine receptor 1 (RyR2), a major regulator of 
sarcoplasmic release of stored calcium ions. It can reduce calcium sparks and thus 
arrhythmogenic calcium waves in the heart.  
Following the initial demonstration that flecainide acetate possessed antibacterial activity 
against planktonic E. coli at 10 µM, it was further evaluated using standard procedures. Against 
planktonic cultures of S. aureus SH1000 and E. coli 1411 flecainide acetate exhibited MICs of 
0.5 µg/mL and 1 µg/mL respectively. When used for its clinically approved indication as an oral 
antiarrhythmic agent, flecainide acetate achieves a maximum serum concentration (Cmax) of 0.2-
1 µg/mL.  The MIC values determined against S. aureus SH100 and E. coli 1411 are therefore 
within this therapeutic index.  
Newly discovered antimicrobial agents that exhibit potent, broad-spectrum activity are 
frequently membrane damaging. To determine if this was a property of flecainide acetate, the 
integrity of the S. aureus SH1000 membrane was assessed using the BacLightTM assay. At 4 x 
MIC, flecainide acetate caused a loss of 25% to SH1000 membrane integrity within 10 minutes 
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(Table 5.3). In the BacLightTM assay, a compound is considered to be membrane damaging 
when a >30 % loss of membrane integrity is observed, only 5% greater than that seen for 
flecainide acetate. Since this assay does not reliably detect subtle membrane disruption, or 
perturbation occurring over longer than a 10 minute window, additional assays would need to be 
performed to elucidate the mechanism of action.  
When resupplied with flecainide acetate from the NIH, none of the results outlined in above 
could be reproduced. To determine the active component from the original stock of flecainide 
acetate, a sample was sent for analysis by mass-spectrometry (MS) and high-performance liquid 
chromatography (HPLC) (performed by Dr Martin McPhillie). Results suggested the presence 
of a compound that would have existed as an intermediate in the synthesis of flecainide acetate. 
To determine the specific structure of the unknown intermediate, nuclear magnetic resonance 
(NMR) would need to be performed. However, due to insufficient quantities, NMR could not be 
performed, and further investigations could not be continued.  
 
5.3.2.1 Tocriscreen Total in combination with rifampicin or linezolid 
Tocriscreen Total chemical library was screened in combination with rifampicin and linezolid 
against planktonic E. coli 1411. No potentiators of rifampicin were determined. One compound 
was identified which potentiated the activity of linezolid; the protein kinase A inhibitor, H89 
dihydrochlroide (H 89). In prokaryotic physiology, protein kinases fulfil purposes similar to 
those in eukaryotes, transducing signals to the bacterial chromosome, although they are far less 
complex. The inhibitory action of H89 dihydrochloride is non-specific, and inhibits several 
other kinases, including but not limited to, ribosomal protein S6 kinase beta-1 and 
mitogen/stress activated protein kinase. Subsequently, the ability of H 89 dihydrochloride to 
potentiate the activity of linezolid against planktonic E. coli 1411 could possibly be a result of 
the inhibitory activity of H 89, acting on the efflux pumps, directly compromising their 
function, or indirectly preventing their up-regulation. 
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In addition, this screen identified to two compounds which exhibited antibacterial activity alone 
at the tested concentration of 10 µM; the potent multi-enzyme inhibitor, diphenyleneiodonium 
chloride, and the competitive bradykinin B2 receptor antagonist, WIN 64338 hydrochloride. 
Diphenyleneiodium chloride is a eukaryotic agonist of G-protein coupled receptor 3, a member 
of the G-protein coupled receptor family (Ye et al., 2014). It also binds strongly to 
flavoproteins, inhibiting a number of enzymes, including NO synthase, NADPH oxidases and 
NADPH cytochrome P450 oxidoreductase (Stuehr et al., 1991, Tew, 1993, Yea et al., 1990, 
Wang et al., 1993). Diphenyleneidonium chloride also induces Ca2+ mobilization and β-arrestin 
receptor internalization, and inhibits platelet aggregation. Due to the activity of this compound 
affecting multiple enzymes, it is likely that the antibacterial effect observed against planktonic 
E. coli 1411 is due to non-specific effects. As a consequence, potential antibacterial properties 
of diphenyleneiodonium chloride were not investigated further in this study.  
As mentioned above, WIN 64338 hydrochloride is identified as a mammalian, non-peptide, 
competitive bradykinin B2 receptor antagonist (Hu et al., 2004, Scherrer et al., 1995, Marceau et 
al., 1994). In mammals, the bradykinin receptor family is a G-protein coupled receptor that 
stimulates phospholipase C, increasing intracellular calcium and inhibiting adenylate cyclase.  It 
is involved in many pathways, such as inflammation, vasodilation and smooth muscle 
relaxation. Furthermore, as WIN 64338 hydrochloride is not a peptide, it is not subject to poor 
bioavailability and metabolism that would limit other peptide molecules (Sawutz et al., 1994).  
To investigate the properties of H 89 dihydrochloride and WIN 64338 hydrochloride further, 
MICs were determined against S. aureus SH1000, E. coli 1411 and P. aeruginosa PA01 (Table 
5.2). Screening found that H 89 dihydrochloride was able to potentiate the activity of linezolid 
against planktonic E. coli 1411, but here has also been shown to have antibacterial activity 
alone, exhibiting MICs of 64 µg/mL, 16 µg/mL and >256 µg/mL, against SH1000, 1411 and 
PAO1 respectively (Table 5.2). WIN 64338 dihydrochloride had stronger activity, exhibiting 
MICs of 1 µg/mL, 4 µg/mL and 128 µg/mL against SH1000, 1411 and PAO1 respectively 
(Table 5.2). 
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Table 5.2 Minimum inhibitory concentrations (MICs) of H 89 dihydrochloride and WIN 64338 
hydrochloride from the Tocriscreen Total collection, against S. aureus SH1000, E. coli 1411 
and P. aeruginosa PAO1. -0-2 MICs of H89 and WIN 64338 against S. aureus and E. coli 
  Antibacterial Activity (µg/mL) 
Compound 
10µM in 
µg/mL 
S. aureus 
SH1000 
planktonic MIC 
E. coli 1411 
planktonic MIC 
P. aeruginosa 
PAO1 
planktonic MIC 
H 89 
dihydrochloride 
5.19 64 16 >256 
WIN 64338 
hydrochloride 
7.83 1 4 128 
 
Although reasonable activity against S. aureus SH1000 and E. coli 1411 was observed for WIN 
64338 hydrochloride, and a possible synergistic interaction between H 89 dihydrochloride and 
linezolid against E. coli 1411, no pre-clinical whole animal studies on these compounds have 
been performed. Consequently, neither H 89 dihydrochloride nor WIN 64338 was investigated 
further in this study.  
 
5.3.2.2 Spectrum collection in combination with rifampicin and linezolid  
The systematic screening of the Spectrum Collection in combination with rifampicin or 
linezolid against planktonic E. coli 1411 identified 38 compounds that exhibited antibacterial 
activity alone. There were alexidine hydrochloride, azithromycin, aztreonam, bekanamycin 
sulphate, belomycin, ceftinir, ceftibuten, chloramphenicol, ciprofloxacin, doxyclycline 
hydrochloride, enrofloxacin, furazolidone, gatifloxacin, gemifloxacin mesylate, levofloxacin, 
lemofloxacin hydrochloride, meclocycline sulfosalicylate, micocycline hydrochloride, 
mitomycin C, moxifloxacin hydrochloride, nifuroxazide, norfloxacin, ofloxacin, 
oxytetracycline, pefloxacine mesylate, phenylmercuric acetate, polymixin B sulphate, 
pyrithioone zinc, sarafloxacin hydrochloride, sucralose, telithomycin, tetracycline 
hydrochloride, thimersosal, thiogunanine, thiogunanosine, triclosan and zidovudine.  . However 
of the 38 compounds, only 6 were not previously described antimicrobials. Included in those 6 
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were 4 antineoplastic agents; bleomycin, mitomycin C, thioguanine and thioguanosine. 
Antineoplastics are used to inhibit tumours from growing and spreading. The remaining 2 
compounds were sucralose, used to sweeten consumables, and the antiretroviral zidovudine, that 
inhibits viral reverse-transcriptase.  
The screen also identified 11 compounds that potentiated the activity of rifampicin. These were 
cefditorin pivoxil, colistemethate hydrochloride, dirithromycin, doxifluridine, florfenicol, 
floxuridine, fluorouracil, metaraminol bitartrate, methacycline hydrochloride, spectinomycin 
hydrochloride and sulfonomethoxine. In addition, 7 compound were identified that potentiated 
the activity of linezolid against planktonic E. coli 1411. These were colistimethate sodium, 
dirithromycin, doxifluridine, floxuruidine, fluorouracil, methacycline hydrochloride and 
spectinomycin hydrochloride. Only 4 of the 11 rifampicin potentiators were not existing 
antimicrobials. These included the 3 antineoplastic agents doxifluridine, floxuridine and 
fluorouracil, and one antihypotensive known as metaraminol bitartrate, used to raise reduced 
blood pressure. All 7 of the compounds found to potentiate the activity of linezolid were also 
found amongst the 11 compounds that potentiated the activity of rifampicin. Of these, 3 were 
the antineoplastic agents doxifluridine, floxuridine and fluoruracil, and the remaining 4 were 
established antimicrobial agents. 
Since the majority of compounds identified in the Spectrum Collection screen were found to be 
existing antimicrobials, only 10 were investigated further. From the 38 compounds that 
exhibited antibacterial activity alone sucralose, thioguanine and zidovudine were chosen for 
additional analysis, and the remaining 7 compounds were selected from those originally 
determined as being potentiators of rifampicin alone, or both rifampicin and linezolid against E. 
coli 1411. These were dirithromycin, florfenicol, fluorouracil, metaraminol bitartrate, 
methacycline hydrochloride, spectinomycin hydrochloride and sulfamonomethoxine.  
To investigate further the antibacterial activity of these 10 compounds, MICs against S. aureus 
SH1000 and E. coli 1411 were determined. Against SH1000, MICs ranged from 0.5 - >256 
µg/mL, and against 1411, MICs ranged from 0.03125 - >256 µg/mL (Table 5.3). Two of the 
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three nucleoside analogue inhibitors, thioguanine and zidovudine, were found to have no 
activity against S. aureus SH1000, but displayed potent activity against E. coli 1411, exhibiting 
MICs of 0.5 and 0.03 µg/mL, respectively. The third nucleoside analogue , fluorouracil, 
exhibited comparable 1411 activity with an MIC of 1 µg/mL, but was also active against 
SH1000, with an MIC of 8 µg/mL (Table 5.3). Sucralose was one of the compounds that 
exhibited activity alone against planktonic E. coli 1411, however, upon Spectrum resupplying 
this compound, no antibacterial activity was observed (Table 5.3). Of the remaining 6 
compounds, 5 are approved antibacterials; dirithromycin, florfenicol, methacycline 
hydrochloride, spectinomycin hydrochloride and sulfamonomethoxine. Dirithromycin, 
methacycline hydrochloride and spectinomycin hydrochloride were all found to potentiate both 
rifampicin and linezolid activity against planktonic E. coli 1411. All three compounds also 
exhibited antibacterial activity alone. Against SH1000, MICs were 0.5, 1 and 32 µg/mL, for 
dirithromycin, methacycline hydrochloride and spectinomycin hydrochloride respectively. 
Against 1411, dirithcomycin and methacycline hydrochloride exhibited MICs of 4 and 1 µg/mL 
respectively, whilst spectinomycin hydrochloride displayed more potent activity against 1411 
than SH1000, with an MIC of 4 µg/mL (Table 5.3).  
 
The remaining antibacterial, sulfamethoxine, only potentiated the activity of rifampicin, and 
exhibited no antibacterial activity against 1411 or SH1000, when resupplied from Spectrum, 
displaying MICs >256 µg/mL. Finally, metartraminol bitartrate, which was originally identified 
as a potentiator of rifampicin against planktonic E. coli 1411, displayed an MIC against SH1000 
of 32 µg/mL, but lacked activity against 1411, exhibiting an MIC of >256 µg/mL (Table 5.3). 
Metaraminol bitartrate is a eukaryotic α1-adrenergic receptor agonist, used as an 
antihypotensive. 
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Table 5.3 Minimum inhibitory concentrations (MICs) of the 10 compounds identified from the 
Spectrum Collection for preliminary susceptibility studies. MICs were determined against S. 
aureus SH1000 and E. coli 1411. 
   Antibacterial Activity (µg/mL) 
(spectrum follow up) 
Compound 
Function 
 
10µM in 
µg/mL 
S. aureus 
SH1000 
planktonic 
MIC 
E. coli 1411 
planktonic 
MIC 
Dirithromycin Antibacterial 8.35 0.5 4 
Florfenicol Antibacterial 3.58 4 4 
Fluorouracil 
Antineoplastic and 
pyrimidine 
antimetabolite 
1.3 8 1 
Metaraminol bitartrate Antihypotensive 1.67 32 >256 
Methacycline 
hydrochloride 
Antibacterial 4.79 1 1 
Spectinomycin 
hydrochloride 
Antibacterial 4.95 32 4 
Sucralose Sweetener 3.98 >256 >256 
Sulfamonomethoxine Antibacterial 2.80 >256 >256 
Thioguanine 
Antineoplastic and 
purine 
antimetabolite 
1.67 >256 0.5 
Zidovudine 
RT transferase 
inhibitor and 
antiviral 
2.67 >256 0.03125 
 
Following initial susceptibility determinations it was decided to focus the subsequent 
investigations on the 3 three nucleoside analogues fluoruracil, thiogunanine and zidovudine .To 
determine the range of activity of each, susceptibility testing was performed against the so-
called ESKAPE pathogens, which represent the bacteria that are recognised to be the major 
cause of hospital infections in the USA. These are Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pnomoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and 
Enterbacter species. Fluorouracil exhibited MICs ranging from 4 – 64 µg/mL, thioguanine was 
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inactive against all strains tested, with MICs greater than 256 µg/mL, and zidovudine exhibited 
MICs ranging from 4->256 µg/mL (Table 5.4). 
 
Table 5.4 Minimum inhibitory concentrations (MICs) of fluorouracil, thioguanine and 
zidovudine against ESKAPE pathogens. 
 Antibacterial Activity (µg/mL) 
Strain Fluorouracil Thioguanine Zidovudine 
Acinetobacter 
baumanni Cubist 
581217 
8 >256 >256 
Enterobacter cloacae 
Cubist 583750 
4 >256 4 
Escherichia coli 
Cubist IHMA 659048 
8 >256 64 
Klebsiella oxytoca 
Cubist 683079 
16 >256 >256 
Klebsiella 
pneumoniae Cubist 
581436 
64 >256 256 
Pseudomonas 
aeruginosa PA01  
32 >256 >128 
Staphylococcus 
aureus Cubist ACC 
A790662 
32 >256 >256 
 
Table 5-0-MICs of fluorouracil, thioguanidine and zidovudine against the ESKAPE 
pathogens 
Due to the limited activity exhibited by fluorouracil, thioguanine and zidovudine against the 
ESKAPE organisms, compared to that observed in the preliminary determinations’ against E. 
coli, the susceptibility of 8 further E. coli strains was investigated. These included 7 strains that 
were multi-drug resistant, and the wildtype E. coli strain MG1655 (ATCC 700926) (Table 5.5). 
Fluorouracil exhibited a lower MIC against MG1655, than the multi-drug resistant stains, with 
MICs of 2 µg/mL and 16-64 µg/mL respectively (Table 5.5). Thioguanine exhibited no activity 
against any of the 8 E. coli strains tested, with MICs >128 µg/mL and >256 µg/mL, which is 
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comparable the poor activity observed against the ESKAPE pathogens (Table 5.4 and 5.5). Like 
fluorouracil, zidovudine displayed the lowest MIC against MG1655, at 4 µg/mL. This was also 
observed against E. coli Cubist 657524, an E. coli strain possessing enzyme CTX-M-32, which 
is an extended spectrum β-lactamase. Against the remaining E. coli strains, zidovudine MICs 
ranged from 64->256 µg/mL, which is also comparable to the range of activity against the 
ESKAPE pathogens (Table 5.4 and 5.5).  
 
Table 5.5 Minimum inhibitory concentrations (MICs) of fluorouracil, thioguanine and 
zidovudine against 8 strains of E. coli. E. coli strains 
 Antibacterial Activity (µg/mL) 
Strain Fluorouracil Thioguanine Zidovudine 
Escherichia coli 
MG1655 
2 >256 4 
Escherichia coli 
Cubist IHMA 684850 
64 >128 128 
Escherichia coli 
Cubist 449334 
128 >128 >256 
Escherichia coli 
Cubist 586030 
16 >128 128 
Escherichia coli 
Cubist 605879 
32 >128 256 
Escherichia coli 
Cubist 702452 
32 >128 64 
Escherichia coli 
Cubist 657524 
32 >128 4 
Escherichia coli 
Cubist 449742 
16 >128 >256 
 
 
The poor activity of fluorouracil, thioguanine and zidovudine against the 8 E. coli strains was 
therefore comparable to that observed against the ESKAPE pathogens. However, when treating 
infections, it has been frequently suggested that compounds can be used more successfully in 
combination due to a synergistic interaction. This is referred to as synergy. Subsequently, 
88 
 
 
 
attempts were made to determine if combinations of fluorouracil, thioguanine and zidovudine 
were synergistic, against planktonic cultures of E. coli 1411, MG1655 and Cubist 449472 
(Table 5.6). E. coli strain Cubist 449472 contains β-lactamase enzymes CTX-M-15 and TEM-
15. Synergism of fluorouracil with thioguanine was not observed. Indeed, the combination 
exhibited an antagonistic interaction against MG1655, with an FIC equal to 2, and an additive 
effect against 1411 and Cubist 449472, both with an FIC of 1.031 (Table 5.6).  Similarly, 
zidovudine with thioguanine displayed antagonistic activity against MG1655, with an FIC of 2, 
and an additive interaction against 1411 and Cubist 449472, with FICs of 0.56 and 0.625 
respectively (Table 5.6). Fluorouracil with zidovudine acted synergistically against all 3 E. coli 
strains, exhibiting an FIC of 0.265 against 1411 and Cubist 449472 and 0.281 against MG1655 
(Table 5.6). 
Table 5.6 Synergism of fluorouracil with thioguanine, fluorouracil with zidovudine and 
zidovudine with thioguanine against planktonic cultures of E. coli 1411, MG1655 and Cubist 
449472. FIC index < 0.5 is synergistic, equal to 1 is additive and > 2 antagonistic.d zidovudine  
  FIC index  
Compound 
combinations 
E. coli 1411 E. coli MG1655 
E. coli Cubist 
449472 
Fluorouracil and 
thioguanine 
1.031 2 1.031 
Flurouracil and 
Zidovudine 
0.265 0.281 0.265 
Thioguanine and 
Zidovudine 
0.56 2 0.625 
 
 
Fluorouracil and zidovudine were therefore the only combination to exhibit a synergistic 
interaction, and have the potential to be investigated further as novel antibacterial treatment for 
E. coli.  
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5.4 Conclusions 
Since it takes an average of 10-15 years for a drug to go from discovery to clinical use, drug 
repurposing is an attractive approach in the search for novel antimicrobial agents, due to a 
significantly reduced development phase. It is therefore of some significance that this work has 
identified a number of compounds, either as antibacterial agents alone, or as adjuvants for 
existing antibiotics, following this method. Based on preliminary assessment, the unidentified 
flecainide acetate intermediary was the most promising candidate as a broad spectrum 
antibacterial agent, with MICs against S. aureus SH1000 and E. coli 1411 of 1 µg/mL or less, 
activity that is comparable to clinically available antibiotics. .H 89 dihydrochloride 
demonstrated the most potential for repurposing as an antibiotic adjuvant of linezolid against the 
Gram-negative organism E. coli, against which no previous activity has been reported. In 
addition, fluorouracil in combination with zidovudine also exhibited potential as a novel 
treatment of E. coli. Although no anti-staphylococcal, antibiofilm agents were determined, this 
could be attributed to biofilm communities being highly recalcitrant to antimicrobial therapy. 
Ultimately, this work demonstrates that the application of drug repurposing to the search for 
novel antimicrobial agents discovery is a feasible approach, and the publication of screening 
data also holds value in the prevention of repeat investigations.  
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Chapter 6  
General conclusions and future studies 
 
The ability of bacteria to grow in the form of a biofilm provides protection from multiple 
antimicrobial agents and the host immune system (Donlan and Costerton, 2002). Multiple 
mechanisms have been demonstrated to contribute to the recalcitrance of biofilms, such as 
restricted antibiotic penetration and high levels of slow or non-growing (SONG) cells (Lebeaux 
et al., 2014). This type of infection has been shown to be particularly problematic when 
associated with indwelling medical devices (Donlan, 2001). Consequently, there is a pressing 
need for novel antibiofilm treatments. This work therefore focused on strategies in the 
prevention and eradication of biofilms, primarily on implanted medical devices and the 
discovery of new antibiofilm molecules. 
During the initial stages of this study screening of 56 novel antibiofilm molecules (ABMs) was 
performed to determine antimicrobial activity and potential toxicity. Based on these parameters, 
the five most promising ABMs were selected; 4-45, CIM008405, P1a-PEP1, P2-5, Tocris 2611. 
These five compounds exhibited varying spectrums of antimicrobial activity; 4-45 and Tocris 
2611 were predominantly active against Gram-positive species, namely staphylococci. Whilst 
CIM008405 exhibited preferential activity against Gram-negative organisms, notably P. 
aeruginosa. Finally, P1a-PEP1 and P2-5 had potent anti-fungal activity. As all five ABMs 
demonstrated antimicrobial activity against S. aureus, this organism was used as a model to 
investigate the MOA of each compound. Initially, radiolabeled precursors were used to assess 
the effects of the compounds on DNA, RNA and protein biosynthesis. None of the five ABMs 
caused preferential inhibition of any of the macromolecular synthesis pathways. This type of 
non-specific response indicative of compounds which have antimicrobial activity against 
Staphylococcus aureus by disrupting the cytoplasmic membrane, a profile consistent with 
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macromolecular synthesis inhibition described previously (O'Neill and Chopra, 2004, Ooi et al., 
2009, Randall et al., 2013b). Indeed, subsequent experimentation revealed all five ABMs 
significantly compromised the integrity of the membrane and caused rapid membrane 
depolarisation. The membrane was therefore considered to be the antibacterial target. 
Assessment of staphylococcal liposomes demonstrated that four (4-45, CIM008405, P1a-PEP1, 
P2-5) of the five ABMs caused damage as a consequence of direct interaction with the 
phospholipid component of the membrane. An effect that was comparable in mammalian 
liposomes. Furthermore, the four ABMs (4-45, CIM008405, P1a-PEP1, P2-5) induced complete 
or near complete haemolysis of erythrocytes, indicating that these compounds are not 
prokaryote specific. Tocris 2611 only resulted in partial haemolysis of erythrocytes, which 
suggests some bacteria-specific activity. Indeed, after 48 hours exposure to > 30 x MIC Tocris 
2611, human osteoblasts (OB) and bone marrow derived stem cells (MSC) retained 95% 
viability, an effect comparable to the solvent control.  
Although it was demonstrated that Tocris 2611 disrupts the bacterial membrane, the specific 
target of this compound has not been established. The successful generation of staphylococcal 
cell ghosts could enable further elucidation of the MOA of Tocris 2611. Cell ghosts would 
comprise an intact staphylococcal cell envelope, filled with carboxyfluorescein. Comparable to 
the assessment of carboxyfluorescein filled liposomes, leakage of the dye from cell ghosts could 
be monitored upon exposure to Tocris 2611. Since Tocris 2611 did not cause damage to 
carboxyfluorescein liposomes (comprised of just phospholipid), release of the dye from cell 
ghosts would indicate direct membrane perturbation, most likely as a consequence of interaction 
with the protein component. If cell ghosts remained intact, and no dye was released, it may 
suggest that the compounds interaction with the membrane is dependent on the membrane being 
energised. As discussed in Chapter 4, the generation of staphylococcal cell ghosts has not been 
previously reported, however the successful production of E. coli cells ghost has been 
demonstrated through the controlled expression of phage lysis gene E (Langemann et al., 2010).  
The phage lysis gene E allows the intracellular contents to leave the cell through a 
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transmembrane tunnel structure, formed in the cell envelope by phage lysis gene E(Langemann 
et al., 2010). This is now being adapted for staphylococci. To confer staphylococcal activity a 
chimeric E-L lysis gene is being generated. However, when being used in staphylococci, 
membrane vesicles are required to reseal the transmembrane pores (Lubitz, 2010) . In addition, 
as indicated in Chapter 4, attempts were made to generate carboxyfluorescein filled 
staphylococcal cell ghosts in a similar manner to the liposome assay described in this chapter. 
Briefly, staphylococcal liposomes (generated as outlined in the liposome assay described in this 
thesis), were mixed in a ratio of 4:1 with staphylococcal membrane extracts, and subjected to 
freeze thawing, before being purified by column chromatography. However, this method 
requires further experimentation. 
Additional insight into the antimicrobial MOA of Tocris 2611 could be provided by further 
resolution of resistant mutants. The activity of Tocris 2611 could be investigated against strains 
in which individual mutations have been introduced, to confirm which alterations in the DNA 
sequence confer a reduced Tocris 2611 susceptibility. Alternatively, techniques such as 
markerless gene deletion in S. aureus could be used to investigate which genes specifically 
resulted in reduced susceptibility to Tocris 2611 (Kato and Sugai, 2011). This could 
subsequently provide information as to the intracellular bacterial target of Tocris 2611. It was 
suggested in section 4.4.4.2 that Tocris resistant strain (T2) had phenotypical alterations to the 
membrane mutations in membrane modifying protein MprF (SAOUHSC_01359), putative long-
chain acyl-CoA synthetase (SAOUHSC_00198) and DNA-directed RNA polymerase 
(SAOUHSCE_02485) as a result of Tocris 2611 exposure. To investigate this further the 
membrane fluidity, surface charge and fatty acid content could be measured in the wildtype 
strain S. aureus SH1000, the resistant strain T2, and a strain in which the mutations had been 
deleted, and then compared to determine that alterations which were specifically responsible for 
resistance to Tocris 2611. 
The method differential radial capillary action of ligand assay (DRaCALA) could also be used 
to evaluate further the cellular target of Tocris 2611 (Roelofs et al., 2011). However, this 
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method would require a radio/fluorescent label on the drug. Furthermore, cross-
resistance/susceptibility of the Tocris 2611 resistant strain against a range of compounds, 
including membrane-damaging agents and approved antimicrobials, could be assessed. A 
change in susceptibility to alternative compounds could indicate mutations associated with 
common mechanisms of resistance, such as the production of antibacterial degrading enzymes 
and changes in the permeability of the bacterial membrane.  
Tocris 2611 also exhibited the ability to eradicate pre-formed staphylococcal biofilms, as well 
as prevent their formation. This unusual property was a consequence of the potent bactericidal 
activity of Tocris 2611 against SONG cells, resulting in their sterilisation. SONG cells are an 
important component of biofilms, forming sub-populations against which the majority of 
antimicrobials are ineffective, and are capable of repopulating the biofilm when antibiotic 
treatment is discontinued. Up to 80% of bacterial infections are believed to include a biofilm 
component, which contributes to recurrent infections and treatment failure. Therefore, agents 
with antibiofilm activity are highly sought after.  
To determine the efficacy of ABM coated implant surfaces, compounds were covalently bound 
to titanium surfaces and assessed for their ability to retain biofilm prevention activity in vivo 
and in vitro. ABM 4-45 was replaced with derivative LC0024 due reduced toxicity to eukaryotic 
cells, whilst maintaining comparable levels of bacterial killing. Two surface types were 
generated; smooth and open porous. Open porosity is favourable due to the promotion of 
osseointegration. These surfaces do however exhibit an increased risk of biofilm-associated 
infection in patients as a consequence of enhanced bacterial adherence. The ABM-coated 
titanium substrates (smooth and open porous) displayed varying levels of biofilm inhibition in 
vitro, but were unable to prevent biofilm formation in vivo. In contrast, control agents 
vancomycin and caspofungin retained activity both in vitro and in vivo, preventing the 
formation of S. aureus and C. albicans biofilms, respectively. Despite this, these drugs are 
amongst the remaining ‘last resort’ antimicrobials. Therefore the use of these agents in implant 
surfaces would be inadvisable due to the promotion of bacterial resistance, and the subsequent 
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loss of any valid treatment to control the infection. Since four (4-45, CIM008405, P1a-PEP1, 
P2-5) of the five ABMs were found to lack prokaryote specificity, and failed to significantly 
reduce biofilm formation when bound to a surface, these compounds would be unsuitable for 
use as antimicrobial therapies. The exact cause of the ABMs loss of activity upon surface 
conjugation it is not yet known, however it could be due to achieving insufficient concentrations 
of the compound on the surface, rapid accumulation of serum proteins, forming a protective 
layer between the active compound and the surrounding environment, or a direct consequence 
of covalent binding of the compound to the surface. To progress these antibiofilm coatings, 
future experimentation could include the use of alternative linker molecules or surface 
conjugation via a different site on the compound. Furthermore, surfaces could be engineered to 
incorporate molecules that prevent the adhesion of serum proteins in order to optimise the 
antibiofilm effect of the adhered ABM.  
Although surface bound Tocris 2611 also lacked antibiofilm activity in vivo, it was 
demonstrated to have potent anti-staphylococcal, antibiofilm activity, and exhibited partial 
prokaryote specificity. In addition, S. aureus developed only low-level resistance as a 
consequence of prolonged exposure to Tocris 2611. This compound would therefore most likely 
be unsuitable as for use as a systemic antibiotic due to potential toxicity, but may have potential 
as a topical treatment for biofilm associated staphylococcal infections. However, development 
of Tocris 2611 for clinical use would require additional in vivo investigations. Preferably, 
animal models would be used that were representative of both infections caused from surgical 
entry and those present in chronic wounds.  
Whilst the ABM-coated implants, generated as part of the COATIM project, failed to inhibit 
microbial biofilm formation, no negative effects on osseointegration were observed. 
Furthermore, a significant reduction in biofilm growth was demonstrated for coatings 
incorporating vancomycin and caspofungin. Although agents such as vancomycin and 
caspofungin would be unsuitable for this purpose, this work has established a viable method for 
the surface immobilisation of molecules through covalent binding with a novel linker. 
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Therefore, results present a proof of concept approach, contributing to the development of next 
generation antibiofilm coatings, in addition to providing potential for exploitation by industry. 
Future work could therefore include the application of alternative antimicrobial compounds to 
implant surfaces using the methodology developed here. 
 
Finally, in attempt to identify additional antibiofilm treatments for staphylococcal infections, 
three small compound chemical libraries were screened for potentiators of known antibiotics 
ciprofloxacin and rifampicin. Libraries were also screened for potentiators of rifampicin, 
linezolid and fusidic acid against E. coli, another well-known human pathogen. At the 
concentrations tested, screening did not reveal any combinations that lead to the eradication of 
pre-formed S. aureus biofilms. Subsequent screening, against planktonic E. coli, detected a 
number of compounds with antibacterial activity, or potentiating effects of rifampicin and 
linezolid. However, further evaluation determined that these agents did not possess useful 
antibacterial activity. Drug repurposing and the use of antibiotic adjuvants has previously been 
regarded as an attractive approach to antibiotic drug discovery, due to a decreased risk of 
resistance, and reduced costs and time associated with development. Although these strategies 
clearly provide some advantages, results presented here suggest these methods are inefficient, 
requiring vast numbers of compounds to be screened for limited output. Furthermore, 
compounds that have undergone a degree of pre-clinical assessment frequently encounter issues 
regarding intellectual property, inhibiting their use (at least while the patent exists) in alternative 
therapies. Therefore, strategies such as these cannot be used as the only approach to the 
discovery and development of novel antibacterial therapeutics, but instead be used alongside 
other approaches such as natural product discovery. 
Since library screening identified no compound or compound/antibiotic combinations that led to 
the eradication of pre-formed staphylococcal biofilms, it may be beneficial to increase the tested 
concentration in subsequent experiments. If agents were identified that exhibited unexpected 
antibacterial activity, further in vitro investigation could be performed to determine their 
96 
 
 
 
potential for repurposing as novel treatments of bacterial infections. Experimentation could 
include, but would not be limited too, extensive susceptibility testing, including antibiofilm 
activity (both prevention and eradication), evaluation of toxicity (i.e. selective or non-selective 
towards bacteria) and MOA characterisation, using approaches such as those outlined in 
Chapters 3 and 4.  
In summary, the work described in this thesis has provided several insights that may be of 
benefit in the development of novel approaches in the treatment and prevention of biofilm 
associated infections. For example, it is apparent that compounds with membrane damaging 
effects may be a useful source of antibiofilm agents. Indeed, membrane damager Tocris 2611 
makes an interesting candidate as an anti-staphylococcal, antibiofilm agent, and could 
potentially be utilised in topical creams. However, future studies would need to be performed to 
elucidate the exact antibacterial target within the cytoplasmic membrane. Despite advances in 
the development of antibiofilm coatings, no compounds were identified that retained antibiofilm 
activity when immobilised to a surface. Leaving a significant amount of development needed in 
the area of antibiofilm coatings and strategies in the healthcare setting. Finally, studies 
investigating the repurposing potential of agents highlighted that this approach cannot be 
reliably used as the sole method for the discovery of new antimicrobial drugs. However, 
collectively this research could facilitate the development of novel approaches in the treatment 
and prevention of biofilm associated infections. 
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Appendices 
Appendix A – Primers used in this study 
 
Oligonucleotide 
primer 
Sequence (5’-3’) 
SAOUHSC_00467 F TTATGAGGCCTTAGAAAATCGAGA 
SAOUHSC_00467 R CAACCGCATTTGCCAATGAAA 
SAOUHSC_01070 F TGTTGGTTATGCGTTTAATGATGT 
SAOUHSC_01070 R CGAGTCAGATGCTAGTTAGTGGT 
SAOUHSC_01359 F TAACTTAACGATTGTTTACGATGCT 
SAOUHSC_01359 R GGCATTTTCATCACCTAACGGA 
SAOUHSC_01621 F AAATGACCACTTGAATGCTTTTTG 
SAOUHSC_01621 R ACGTTTGAAGGAGTTAAAAATGAGT 
SAOUHSC_02485 F TGTTGCAATTTTAAGCTCTGGG 
SAOUHSC_02485 R AAATGGTGTAGCACACATCCG 
SAOUHSC_02659 F TACACAATGTTCATCAATACGTTCA 
SAOUHSC_02659 R TTGCTCCGGAAACGTAACTG 
219191 F CACCGAGTAGGGTAGCTAAGG 
219191 R TGGCGATATATTTATTATTGACCGC 
244311-120 F TCAAGGTCTTTTTCACTATCAACC 
244311-120 R CTCATCTTCCATATCTGCGAGT 
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Appendix B – Activity of novel antimicrobial agents and control agents (ciprofloxacin and gentamicin) against S. aureus SH1000, USA300 
and UAMS-1 and S. epidermidis RP62A.   
Biofilm minimum inhibitory concentrations (bMICs) and minimum biofilm eradication concentration (MBEC) determined in the Calgary Biofilm Device. ND 
indicates not determined. 
 
Antibacterial 
Agent 
Minimum inhibitory concentration (MIC) 
(µM) 
Biofilm minimum inhibitory concentration 
(bMIC) (µM) 
Minimum biofilm eradication 
concentration (MBEC) (µM) 
SH1000 USA300 UAMS-1 RP62A SH1000 USA300 UAMS-1 RP62A SH1000 USA300 UAMS-1 RP62A 
Cirprofloxacin 6.25 100 25 25 12.5 100 25 25 > 100 > 100 > 100 > 100 
Gentamicin 6.25 6.25 100 3.125 6.25 12.5 100 6.25 > 100 > 100 > 100 > 100 
25458 25 25 25 25 50 50 25 50 >100 >100 >100 >100 
42170 25 25 25 25 50 25 25 50 >100 100 >100 >100 
4-1 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
4-3 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
4-4 > 100 > 100 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
4-5 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
4-29 100 100 100 100 > 100 100 > 100 100 > 100 > 100 > 100 > 100 
4-32 50 25 25 50 50 50 50 50 > 100 > 100 > 100 > 100 
4-45 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 > 100 > 100 > 100 > 100 
4-108 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
4-118 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
4-122 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
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Antibacterial 
Agent 
Minimum inhibitory concentration (MIC) 
(µM) 
Biofilm minimum inhibitory concentration 
(bMIC) (µM) 
Minimum biofilm eradication 
concentration (MBEC) (µM) 
SH1000 USA300 UAMS-1 RP62A SH1000 USA300 UAMS-1 RP62A SH1000 USA300 UAMS-1 RP62A 
5-16 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
5-21 6.25 12.5 6.25 12.5 12.5 12.5 12.5 12.5 > 100 > 100 > 100 > 100 
5-59 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
5-79 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
5-86 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
5-102 > 100 100 100 50 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
5-118 100 100 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
5-119 100 100 100 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
5-130 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
8339 > 100 > 100 100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
BCF-AA022 ND ND ND ND 50 50 50 50 > 100 > 100 > 100 > 100 
BCF-AA045 ND ND ND ND 12.5 6.25 12.5 6.25 100 > 100 > 100 > 100 
BS-285 > 100 100 > 100 100 > 100 100 > 100 > 100 > 100 > 100 > 100 > 100 
BS-342 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
CIM003592 ND ND ND ND 50 50 50 50 > 100 > 100 > 100 > 100 
CIM006387 > 100 100 100 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
CIM007844 100 100 100 100 > 100 100 100 100 > 100 > 100 > 100 > 100 
CIM008405 25 25 25 25 25 25 25 25 > 100 > 100 > 100 > 100 
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Antibacterial 
Agent 
Minimum inhibitory concentration (MIC) 
(µM) 
Biofilm minimum inhibitory concentration 
(bMIC) (µM) 
Minimum biofilm eradication 
concentration (MBEC) (µM) 
SH1000 USA300 UAMS-1 RP62A SH1000 USA300 UAMS-1 RP62A SH1000 USA300 UAMS-1 RP62A 
DEB-20 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
DEB-24 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
DEB-28 50 50 50 50 > 100 50 > 100 100 > 100 > 100 > 100 > 100 
P1a-CIM01 100 100 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
P1a-CIM02 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
P1a-CIM03 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
P1a-P1 ND ND ND ND > 100 100 100 > 100 > 100 > 100 > 100 > 100 
P1a-PEP1 ND ND ND ND > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
P1a-PEP2 ND ND ND ND > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
P1a-PEP3 ND ND ND ND 100 100 100 100 > 100 > 100 > 100 > 100 
P1a-PEP4 ND ND ND ND > 100 > 100 100 > 100 > 100 > 100 > 100 > 100 
P1a-PEP5 ND ND ND ND 100 50 25 50 > 100 > 100 > 100 > 100 
P1a-PEP6 ND ND ND ND > 100 100 50 100 > 100 > 100 > 100 > 100 
P1a-PEP7 ND ND ND ND 25 25 25 25 > 100 > 100 > 100 > 100 
P1a-PEP8 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
P1a-PEP9 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
P1a-PEP10 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
P1a-PEP11 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
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Antibacterial 
Agent 
Minimum inhibitory concentration (MIC) 
(µM) 
Biofilm minimum inhibitory concentration 
(bMIC) (µM) 
Minimum biofilm eradication 
concentration (MBEC) (µM) 
SH1000 USA300 UAMS-1 RP62A SH1000 USA300 UAMS-1 RP62A SH1000 USA300 UAMS-1 RP62A 
P2-1 > 100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
P2-5 50 50 25 50 50 50 50 50 >100 >100 >100 >100 
P2-8 25 12.5 25 25 50 12.5 50 12.5 50 25 100 25 
P2-14 50 50 50 50 50 50 50 50 >100 >100 >100 >100 
OSIP108 > 100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
Specs > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
Tocris 2217 50 50 25 50 > 100 100 > 100 100 > 100 > 100 > 100 100 
Tocris 2611 < 0.4 < 0.4 < 0.4 < 0.4 < 0.4 < 0.4 < 0.4 < 0.4 12.5 6.25 12.5 12.5 
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